SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13E-3
RULE 13E-3 TRANSACTION STATEMENT
UNDER SECTION 13(E) OF
THE SECURITIES EXCHANGE ACT OF 1934
NEUEHEALTH, INC.
(Name of the Issuer)
NeueHealth, Inc.
NH Holdings 2025, Inc.
NH Holdings Acquisition 2025, Inc.
NH Holdings 2025 SPV, L.P.
NH Holdings 2025 GP, LLC
NEA 18 Venture Growth Equity, L.P.
New Enterprise Associates 17, L.P.
New Enterprise Associates 16, L.P.
New Enterprise Associates 15, L.P.
NEA 15 Opportunity Fund, L.P.
NEA BH SPV, L.P.
NEA BH SPV II, L.P.
NEA Partners 15, L.P.
NEA Partners 15-OF, L.P.
NEA 15 GP, LLC
NEA Partners 16, L.P.
NEA 16 GP, LLC
NEA Partners 17, L.P.
NEA 17 GP, LLC
NEA Partners 18 VGE, L.P.
NEA 18 VGE GP, LLC
NEA BH SPV GP, LLC
(Names of Persons Filing Statement)
Common stock, par value $0.0001 per share
(Title of Class of Securities)

10920V404
(CUSIP Number of Class of Securities)

NeueHealth, Inc.
c/o 9250 NW 36th St.,
Suite 420
Doral, FL
33178
(612) 238-1321
Attn: Jeff Craig
NH Holdings 2025, Inc.
NH Holdings Acquisition 2025, Inc.
NH Holdings 2025 SPV, L.P.
NH Holdings 2025 GP, LLC
NEA 18 Venture Growth Equity, L.P.
New Enterprise Associates 17, L.P.
New Enterprise Associates 16, L.P.
New Enterprise Associates 15, L.P.
NEA 15 Opportunity Fund, L.P.
NEA BH SPV, L.P.
NEA BH SPV II, L.P.
NEA Partners 15, L.P.
NEA Partners 15-OF, L.P.
NEA 15 GP, LLC
NEA Partners 16, L.P.
NEA 16 GP, LLC
NEA Partners 17, L.P.
NEA 17 GP, LLC
NEA Partners 18 VGE, L.P.
NEA 18 VGE GP, LLC
NEA BH SPV GP, LLC

c/o NEA Management Company, LLC
1945 Greenspring Dr., Suite 600
Timonium, MD
21093
(410) 842-4000
Attn: Stephanie Brecher
(Name, Address, and Telephone Numbers of Person Authorized to Receive Notices
and Communications on Behalf of the Persons Filing Statement)
With copies to
Simpson Thacher & Bartlett LLP
2475 Hanover Street
Palo Alto, CA 94304
Email: aazher@stblaw.com;
wbrentani@stblaw.com
Attention: Atif I. Azher; William B.
Brentani
Latham & Watkins LLP
330 North Wabash Ave, Suite 2800
Chicago, IL 60611
Email:daniel.breslin@lw.com;
max.schleusener@lw.com
Attention: Daniel Breslin; Max
Schleusener
This statement is filed in connection with (check the appropriate box):
a.
The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934.
b.
The filing of a registration statement under the Securities Act of 1933.
c.
A tender offer.
d.
None of the above.
Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☒
Check the following box if the filing is a final amendment reporting the results of the transaction:
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of this transaction, passed upon the merits or fairness of this transaction or passed upon the adequacy or accuracy of the disclosure in this document. Any representation to the contrary is a criminal offense.

Introduction
This Transaction Statement on Schedule 13E-3 (“Transaction Statement”) is being filed with the U.S. Securities and Exchange Commission (the “SEC”) pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”), jointly by the following persons (each, a “Filing Person” and, collectively, the “Filing Persons”): (1) NeueHealth, Inc., a Delaware corporation (“NeueHealth” or the “Company”); (2) NH Holdings 2025, Inc., a Delaware corporation (“Parent”); (3) NH Holdings Acquisition 2025, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”); (4) NH Holdings 2025 SPV, L.P., a Delaware limited partnership of which Parent is a wholly owned subsidiary (“Ultimate Parent”); (5) NH Holdings 2025 GP, LLC, a Delaware limited liability company of which Ultimate Parent is a wholly owned subsidiary (“GP Holdings”); (6) the following investment funds or vehicles affiliated with or managed by New Enterprise Associates (collectively, the “NEA Stockholders”): NEA 18 Venture Growth Equity, L.P., a Delaware limited partnership, New Enterprise Associates 17, L.P., a Delaware limited partnership, New Enterprise Associates 16, L.P., a Delaware limited partnership, New Enterprise Associates 15, L.P., a Delaware limited partnership, NEA 15 Opportunity Fund, L.P., a Delaware limited partnership, NEA BH SPV, L.P., a Delaware limited partnership, and NEA BH SPV II, L.P., a Delaware limited partnership; and (7) NEA Partners 15, L.P., a Delaware limited partnership, NEA Partners 15-OF, L.P., a Delaware limited partnership, NEA 15 GP, LLC, a Delaware limited liability company, NEA Partners 16, L.P., a Delaware limited partnership, NEA 16 GP, LLC, a Delaware limited liability company, NEA Partners 17, L.P., a Delaware limited partnership, NEA 17 GP, LLC, a Delaware limited liability company, NEA Partners 18 VGE, L.P., a Delaware limited partnership, NEA 18 VGE GP, LLC, a Delaware limited liability company, and NEA BH SPV GP, LLC, a Delaware limited liability company. Each of Parent, Merger Sub, Ultimate Parent and GP Holdings is indirectly controlled by investment funds affiliated with NEA.
This Transaction Statement relates to the Agreement and Plan of Merger, dated as of December 23, 2024 (as it may be amended, supplemented or modified from time to time, the “Merger Agreement”), by and among the Company, Parent and Merger Sub, pursuant to which, among other things and on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. The Merger Agreement and the transactions contemplated thereby, including the Merger, are more fully described in the proxy statement (the “Proxy Statement”) filed by the Company with the SEC under Regulation 14A of the Exchange Act concurrently with the filing of this Transaction Statement.
In connection with the execution of the Merger Agreement, certain stockholders of the Company (the “Rollover Holders”) entered into rollover agreements (the “Rollover Agreements”) with Ultimate Parent, Parent and Merger Sub, pursuant to which, among other things and on the terms and subject to the conditions set forth therein, the Rollover Holders have agreed to contribute all of their shares of common stock of the Company, par value $0.0001 per share (the “Company Common Stock”), Series A Convertible Perpetual Preferred Stock of the Company, par value $0.0001 per share (the “Company Series A Preferred Stock”), and/or Series B Convertible Perpetual Preferred Stock of the Company, par value $0.0001 per share (the “Company Series B Preferred Stock” and, together with the Company Series A Preferred Stock, the “Company Preferred Stock”), to Ultimate Parent immediately prior to the effective time of the Merger (the “Effective Time”) in exchange for the issuance to the Rollover Holders of limited partnership interests in Ultimate Parent. Additionally, certain of the Rollover Holders have agreed pursuant to their respective Rollover Agreements, on the terms and subject to the conditions set forth therein, to vote all of their shares of Company Common Stock and/or Company Preferred Stock in favor of the adoption of the Merger Agreement.
The Merger Agreement provides that, at the Effective Time, each share of Company Common Stock that is issued and outstanding immediately prior to the Effective Time (other than shares owned immediately prior to the Effective Time by the Company, Ultimate Parent, Parent, Merger Sub or any of their respective subsidiaries (including shares contributed to Ultimate Parent prior to the Effective Time pursuant to the Rollover Agreements or other similar agreements), which will be canceled for no consideration, and Dissenting Shares (as defined below)) will be converted into the right to receive $7.33 in cash, without interest and less any applicable withholding taxes. Shares of Company Common Stock and Company Preferred Stock with respect to which a demand for appraisal has been validly made (and not forfeited or withdrawn) in accordance with Delaware law (“Dissenting Shares”) will be entitled to receive payment of the appraised value of such shares as provided by Delaware law.
1

The effect of the Merger, if consummated, on the Company’s options to purchase shares of Company Common Stock, restricted stock units with respect to shares of Company Common Stock and warrants to purchase shares of Company Common Stock is described in the Proxy Statement.
The board of directors of the Company (the “Company Board”) formed a special committee comprised solely of disinterested and independent members of the Company Board (the “Special Committee”), which, among other things, reviewed, evaluated and negotiated the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger, in consultation with its legal and financial advisors and, where appropriate, with Company management and the Company’s legal advisors. The Special Committee unanimously (1) determined that the Merger Agreement and the transactions contemplated thereby, including the Merger, are fair to, and in the best interests of, the Company and the holders of shares of Company Common Stock (other than shares of Company Common Stock held by or on behalf of the NEA Stockholders, the Rollover Holders and any other stockholders of the Company that are affiliated with the NEA Stockholders, the Rollover Holders, Parent, Merger Sub or any of their respective affiliates (collectively, the “Public Stockholders”)), and (2) recommended that the Company Board (i) approve and declare advisable the Merger Agreement and the transactions contemplated thereby, including the Merger, and (ii) recommended that the stockholders of the Company approve and adopt the Merger Agreement in accordance with the certificate of incorporation and bylaws of the Company and the Delaware General Corporation Law (the “DGCL”). In addition, the Special Committee believes that the Merger is fair to the Company’s “unaffiliated security holders,” as such term is defined in Rule 13e-3 under the Exchange Act.
The Company Board, acting upon the recommendation of the Special Committee, unanimously (1) determined that the Merger Agreement and transactions contemplated thereby, including the Merger, are fair to, and in the best interests of, the Company and its stockholders, including the Public Stockholders, (2) approved and declared advisable the Merger Agreement and the transactions contemplated thereby, including the Merger, (3) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Merger, on the terms and subject to the conditions set forth therein, and (4) recommended that the stockholders of the Company approve and adopt the Merger Agreement in accordance with the certificate of incorporation and bylaws of the Company and the DGCL.
The Merger cannot be completed without the affirmative vote of the holders of a majority of the voting power of the outstanding shares of Company Common Stock and Company Preferred Stock (voting on an as-converted basis), voting together as a single class, that are entitled to vote on the adoption of the Merger Agreement.
If the Merger is consummated, the Company Common Stock will be delisted from the New York Stock Exchange and deregistered under the Exchange Act.
Concurrently with the filing of this Transaction Statement, the Company is filing with the SEC, under Regulation 14A of the Exchange Act, the Proxy Statement, pursuant to which the Company is soliciting proxies from stockholders of the Company in connection with the Merger. The Proxy Statement is attached hereto as Exhibit (a)(1). A copy of the Merger Agreement is attached to the Proxy Statement as Annex A. As of the date hereof, the Proxy Statement is in preliminary form and is subject to completion or amendment. Terms used but not defined in this Transaction Statement have the meanings assigned to them in the Proxy Statement.
Pursuant to General Instruction F to Schedule 13E-3, the information in the Proxy Statement, including all annexes thereto, is expressly incorporated by reference herein in its entirety, and responses to each item herein are qualified in their entirety by the information contained in the Proxy Statement and the annexes thereto. The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the Proxy Statement of the information required to be included in response to the items of Schedule 13E-3.
While each of the Filing Persons acknowledges that the Merger may be deemed to constitute a “going private” transaction for purposes of Rule 13e-3 under the Exchange Act, the filing of this Transaction Statement shall not be construed as an admission by any Filing Person, or by any affiliate of a Filing Person, that the Company is “controlled” by any of the Filing Persons and/or their respective affiliates.
All information contained in, or incorporated by reference into, this Transaction Statement concerning each Filing Person has been supplied by such Filing Person. No Filing Person, including the Company, is responsible for the accuracy of any information supplied by any other Filing Person.
2

Item 1.
Summary Term Sheet
Regulation M-A Item 1001
The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
Item 2.
Subject Company Information
Regulation M-A Item 1002
(a) Name and address. NeueHealth’s name, and the address and telephone number of its principal executive offices are:
NeueHealth, Inc.
9250 NW 36th St., Suite 420
Doral, FL 33178
Tel: (612) 238-1321
(b) Securities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“THE SPECIAL MEETING—Record Date and Quorum”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Security Ownership of Certain Beneficial Owners and Management”
(c) Trading market and price. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Market Price of Company Common Stock and Dividends”
(d) Dividends. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Market Price of Company Common Stock and Dividends”
“THE MERGER AGREEMENT—Conduct of the Business Pending the Closing”
(e) Prior public offerings. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Prior Public Offerings”
(f) Prior stock purchases. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
“THE MERGER AGREEMENT”
“THE ROLLOVER AGREEMENTS”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Certain Transactions in the Shares of Company Common Stock”
Annex A – Agreement and Plan of Merger, dated as of December 23, 2024, by and among NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc., and NeueHealth, Inc.
Annex B – Form of Rollover Agreement
3

Item 3.
Identity and Background of Filing Person
Regulation M-A Item 1003
The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
(a) – (b) Name and address; Business and background of entities.
“SUMMARY TERM SHEET—Parties to the Merger”
“PARTIES TO THE MERGER”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Directors and Executive Officers of the Company”
“OTHER IMPORTANT INFORMATION REGARDING THE PARENT FILING PARTIES”
“WHERE YOU CAN FIND MORE INFORMATION”
(c) Business and background of natural persons.
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Directors and Executive Officers of the Company”
“OTHER IMPORTANT INFORMATION REGARDING THE PARENT FILING PARTIES”
“WHERE YOU CAN FIND MORE INFORMATION”
Item 4.
Terms of the Transaction
Regulation M-A Item 1004
(a) Material terms.
(1) Tender offer. Not applicable
(2) Merger or similar transactions.
(i) A brief description of the transaction; the information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Effective Time of the Merger”
“SPECIAL FACTORS—Payment of Merger Consideration”
“THE MERGER AGREEMENT—Conditions to Closing”
(ii) The consideration offered to security holders; the information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Payment of Merger Consideration”
“THE MERGER AGREEMENT—Treatment of the Shares of Company Common Stock”
“THE MERGER AGREEMENT—Treatment of Company Equity Awards”
(iii) The reasons for engaging in the transaction; the information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
4

“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
“SPECIAL FACTORS—Plans for the Company After the Merger”
“SPECIAL FACTORS—Opinion of Lincoln International LLC”
“SPECIAL FACTORS—Unaudited Prospective Financial Information of the Company”
“SPECIAL FACTORS—Certain Effects of the Merger”
Annex B – Form of Rollover Agreement
Annex C – Opinion of Lincoln International LLC
(iv) The vote required for approval of the transaction; the information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“THE SPECIAL MEETING—Vote Required”
(v) An explanation of any material differences in the rights of security holders as a result of the transaction, if material; the information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
“SUMMARY TERM SHEET”
“SPECIAL FACTORS—Certain Effects of the Merger”
(vi) A brief statement as to the accounting treatment of the transaction, if material; the information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
“SPECIAL FACTORS—Accounting Treatment”
(vii) The federal income tax consequences of the transaction, if material; the information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
“SPECIAL FACTORS—Material U.S. Federal Income Tax Consequences of the Merger”
(c) Different terms. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Certain Effects of the Merger”
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger”
“THE MERGER AGREEMENT—Treatment of the Shares of Company Common Stock”
“THE MERGER AGREEMENT—Treatment of Company Equity Awards”
“THE ROLLOVER AGREEMENTS”
(d) Appraisal rights. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Appraisal Rights”
5

(e) Provisions for unaffiliated security holders. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
“SPECIAL FACTORS—Provisions for Stockholders”
(f) Eligibility for listing or trading. Not applicable.
Item 5.
Past Contacts, Transactions, Negotiations and Agreements
Regulation M-A Item 1005
(a)(1) – (2) Transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger”
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger”
“THE MERGER AGREEMENT—Treatment of the Shares of Company Common Stock”
“THE MERGER AGREEMENT—Treatment of Company Equity Awards”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Certain Transactions in the Shares of Company Common Stock”
(b) – (c) Significant corporate events; Negotiations or contacts. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger”
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger”
“SPECIAL FACTORS—Material U.S. Federal Income Tax Consequences of the Merger”
“SPECIAL FACTORS—Financing of the Merger”
“SPECIAL FACTORS—Limited Guaranty”
“THE MERGER AGREEMENT”
“THE ROLLOVER AGREEMENTS”
Annex A – Agreement and Plan of Merger, dated as of December 23, 2024, by and among NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc., and NeueHealth, Inc.
Annex B – Form of Rollover Agreement
(e) Agreements involving the subject company’s securities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Plans for the Company After the Merger”
6

“SPECIAL FACTORS—Financing of the Merger”
“SPECIAL FACTORS—Limited Guaranty”
“THE MERGER AGREEMENT”
“THE ROLLOVER AGREEMENTS”
“THE SPECIAL MEETING—Vote Required”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Certain Transactions in the Shares of Company Common Stock”
Annex A – Agreement and Plan of Merger, dated as of December 23, 2024, by and among NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc., and NeueHealth, Inc.
Annex B – Form of Rollover Agreement
Item 6.
Purposes of the Transaction, and Plans or Proposals.
Regulation M-A Item 1006
(b) Use of securities acquired. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“SPECIAL FACTORS—Plans for the Company After the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger for the Parent Filing Parties”
“SPECIAL FACTORS—Certain Effects on the Company if the Merger Is Not Completed”
“SPECIAL FACTORS—Payment of Merger Consideration”
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Market Price of Common Stock and Dividends”
“DELISTING AND DEREGISTRATION OF THE COMPANY’S COMMON STOCK”
(c)(1) – (8) Plans. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
“SPECIAL FACTORS—Plans for the Company After the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger for the Parent Filing Parties”
“SPECIAL FACTORS—Certain Effects on the Company if the Merger Is Not Completed”
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger”
7

“SPECIAL FACTORS—Financing of the Merger”
“SPECIAL FACTORS—Limited Guaranty”
“THE ROLLOVER AGREEMENTS”
“THE MERGER AGREEMENT—Effects of the Merger; Directors and Officers; Articles of Incorporation; Bylaws”
“THE MERGER AGREEMENT—Conduct of the Business Pending the Closing”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Market Price of Company Common Stock and Dividends”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Directors and Executive Officers of the Company”
“DELISTING AND DEREGISTRATION OF THE COMPANY’S COMMON STOCK”
Annex A – Agreement and Plan of Merger, dated as of December 23, 2024, by and among NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc., and NeueHealth, Inc.
Annex B – Form of Rollover Agreement
Item 7.
Purposes, Alternatives, Reasons and Effects
Regulation M-A Item 1013
(a) Purposes. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
“SPECIAL FACTORS—Plans for the Company After the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger”
(b) Alternatives. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
“SPECIAL FACTORS—Opinion of Lincoln International LLC”
(c) Reasons. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SPECIAL FACTORS—Background of the Merger”
8

“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
“SPECIAL FACTORS—Plans for the Company After the Merger”
“SPECIAL FACTORS— Opinion of Lincoln International LLC”
“SPECIAL FACTORS—Unaudited Prospective Financial Information of the Company”
“SPECIAL FACTORS—Certain Effects of the Merger”
Annex C – Opinion of Lincoln International LLC
(d) Effects. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
“SPECIAL FACTORS—Plans for the Company After the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger for the Parent Filing Parties”
“SPECIAL FACTORS—Certain Effects on the Company if the Merger Is Not Completed”
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger”
“SPECIAL FACTORS—Material U.S. Federal Income Tax Consequences of the Merger”
“SPECIAL FACTORS—Accounting Treatment”
“SPECIAL FACTORS—Financing of the Merger”
“SPECIAL FACTORS—Fees and Expenses”
“SPECIAL FACTORS—Payment of Merger Consideration”
“THE MERGER AGREEMENT—Effects of the Merger; Directors and Officers; Articles of Incorporation; Bylaws”
“THE MERGER AGREEMENT—Treatment of the Shares of Company Common Stock”
“THE MERGER AGREEMENT—Treatment of Company Equity Awards”
“THE MERGER AGREEMENT—Conduct of the Business Pending the Closing”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Market Price of Company Common Stock and Dividends”
“DELISTING AND DEREGISTRATION OF THE COMPANY’S COMMON STOCK”
9

Annex A – Agreement and Plan of Merger, dated as of December 23, 2024, by and among NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc., and NeueHealth, Inc.
Item 8.
Fairness of the Transaction
Regulation M-A Item 1014
(a) – (b) Fairness; Factors considered in determining fairness. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Opinion of Lincoln International LLC”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger”
Annex C – Opinion of Lincoln International LLC
(c) Approval of security holders. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“THE MERGER AGREEMENT—Conditions to the Merger”
“THE SPECIAL MEETING”
Annex A – Agreement and Plan of Merger, dated as of December 23, 2024, by and among NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc., and NeueHealth, Inc.
(d) Unaffiliated representative. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Certain Effects of the Merger”
(e) Approval of directors. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
10

“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Opinion of Lincoln International LLC”
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger”
“THE MERGER (THE MERGER AGREEMENT PROPOSAL—PROPOSAL 1)”
(f) Other offers. Not applicable.
Item 9.
Reports, Opinions, Appraisals and Negotiations
Regulation M-A Item 1015
(a) – (c) Report, opinion or appraisal; Preparer and summary of the report, opinion or appraisal; Availability of documents. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Opinion of Lincoln International LLC”
“WHERE YOU CAN FIND MORE INFORMATION”
Annex C – Opinion of Lincoln International LLC
The reports, opinions or appraisals referenced in this Item 9 will be made available for inspection and copying at the principal executive offices of NeueHealth during its regular business hours by any interested equity security holder of NeueHealth or representative who has been so designated in writing.
Item 10.
Source and Amounts of Funds or Other Consideration
Regulation M-A Item 1007
(a) – (b) Source of funds; Conditions. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
“SUMMARY TERM SHEET”
“SPECIAL FACTORS—Financing of the Merger”
“SPECIAL FACTORS—Limited Guaranty”
“THE MERGER AGREEMENT—Equity Financing”
Equity Commitment Letter, dated December 23, 2024, by and between NEA 18 Venture Growth Equity, L.P., New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P., New Enterprise Associates 15, L.P. and NH Holdings 2025, Inc., is attached hereto as Exhibit (b)(2) and is incorporated herein by reference.
(c) Expenses. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
11

“SPECIAL FACTORS—Fees and Expenses”
“THE MERGER AGREEMENT—Termination”
“THE MERGER AGREEMENT—Company Termination Fee”
“THE MERGER AGREEMENT—Expenses”
(d) Borrowed funds. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SPECIAL FACTORS—Financing of the Merger”
Equity Commitment Letter, dated December 23, 2024, by and between NEA 18 Venture Growth Equity, L.P., New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P., New Enterprise Associates 15, L.P. and NH Holdings 2025, Inc., is attached hereto as Exhibit (b)(2) and is incorporated herein by reference.
Item 11.
Interest in Securities of the Subject Company
Regulation M-A Item 1008
(a) Securities ownership. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Security Ownership of Certain Beneficial Owners and Management”
(b) Securities transactions. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
“THE MERGER AGREEMENT”
“THE ROLLOVER AGREEMENTS”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Certain Transactions in the Shares of Company Common Stock”
Annex A – Agreement and Plan of Merger, dated as of December 23, 2024, by and among NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc., and NeueHealth, Inc.
Annex B – Form of Rollover Agreement
Item 12.
The Solicitation or Recommendation
Regulation M-A Item 1012
(d) Intent to tender or vote in a going-private transaction. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
“SPECIAL FACTORS—Intent to Vote in Favor of the Merger”
“THE SPECIAL MEETING—Vote Required”
“THE SPECIAL MEETING—Existing Stockholders’ Obligation to Vote in Favor of the Merger”
12

“THE ROLLOVER AGREEMENTS”
Annex B – Form of Rollover Agreement
(e) Recommendation of others. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Position of the Parent Filing Parties as to the Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Parent Filing Parties for the Merger”
Item 13.
Financial Statements
Regulation M-A Item 1010
(a) Financial information. The audited consolidated financial statements of the Company for the fiscal years ended December 31, 2023 and 2022 are incorporated herein by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on March 28, 2024 (see “Item 8. Financial Statements and Supplementary Data” beginning on page 65).
The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SPECIAL FACTORS—Certain Effects of the Merger”
“SPECIAL FACTORS—Unaudited Prospective Financial Information of the Company”
“OTHER IMPORTANT INFORMATION REGARDING THE COMPANY—Book Value per Share”
“WHERE YOU CAN FIND MORE INFORMATION”
(b) Pro forma information. Not applicable.
Item 14.
Persons/Assets, Retained, Employed, Compensated or Used
Regulation M-A Item 1009
(a) – (b) Solicitations or recommendations; Employees and corporate assets. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER”
“SPECIAL FACTORS—Background of the Merger”
“SPECIAL FACTORS—Reasons for the Merger; Recommendations of the Special Committee and the Company Board; Fairness of the Merger”
“SPECIAL FACTORS—Purpose and Reasons of the Company for the Merger”
“SPECIAL FACTORS—Fees and Expenses”
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger”
“THE SPECIAL MEETING—Solicitation of Proxies; Payment of Solicitation Expenses”
13

Item 15.
Additional Information
Regulation M-A Item 1011
(b) Golden Parachute Compensation. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
“SUMMARY TERM SHEET”
“QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER—What am I being asked to vote on at the Special Meeting?”
“SPECIAL FACTORS—Certain Effects of the Merger”
“THE MERGER AGREEMENT—Treatment of the Shares of Company Common Stock”
“THE MERGER AGREEMENT—Treatment of Company Equity Awards”
“SPECIAL FACTORS—Interests of Executive Officers and Directors of the Company in the Merger—Golden Parachute Compensation”
“THE SPECIAL MEETING—Time, Place and Purpose of the Special Meeting”
“MERGER-RELATED EXECUTIVE COMPENSATION ARRANGEMENTS (THE MERGER-RELATED COMPENSATION PROPOSAL—PROPOSAL 3)”
(c) Other material information. The information set forth in the Proxy Statement, including all annexes thereto, is incorporated herein by reference.
14

Item 16.
Exhibits
Regulation M-A Item 1016
+
Filed herewith.
**
Certain portions of this exhibit have been redacted and separately filed with the Securities and Exchange Commission pursuant to a request for confidential treatment.
15

SIGNATURE
After due inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated as of February 3, 2025.
NEUEHEALTH, INC.
 
 
 
By:
/s/ Jeffery Michael Craig
 
 
Name: Jeffery Michael Craig
 
 
Title: General Counsel and Corporate Secretary
 
NH HOLDINGS 2025, INC.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NH HOLDINGS ACQUISITION 2025, INC.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NH HOLDINGS 2025 SPV, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NH HOLDINGS 2025 GP, LLC
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA 18 VENTURE GROWTH EQUITY, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEW ENTERPRISE ASSOCIATES 17, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
16

NEW ENTERPRISE ASSOCIATES 16, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEW ENTERPRISE ASSOCIATES 15, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA 15 OPPORTUNITY FUND, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA BH SPV, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA BH SPV II, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA PARTNERS 15, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA PARTNERS 15-OF, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA 15 GP, LLC
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
17

NEA PARTNERS 16, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA 16 GP, LLC
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA PARTNERS 17, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA 17 GP, LLC
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA PARTNERS 18 VGE, L.P.
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA 18 VGE GP, LLC
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
NEA BH SPV GP, LLC
 
 
 
By:
/s/ Stephanie S. Brecher
 
 
Name: Stephanie S. Brecher
 
 
Title: Chief Legal Officer
 
18

Exhibit (c)(2)
 CONFIDENTIAL DRAFT  Project Green Discussion Materials  August 1, 2024 
 

 CONFIDENTIAL DRAFT  Disclaimer and Confidentiality Statement  Lincoln International LLC (“Lincoln”, “us”, or “we”) has been retained by the special committee (the “Committee”) of the board of directors (the “Board”) of NeueHealth, Inc. (collectively with its subsidiaries and affiliates, the “Company”) to act as its financial advisor in connection with a possible Transaction (as defined herein) involving the purchase by investment funds affiliated with New Enterprise Associates, Inc. (collectively, “NEA”) of the common stock of the Company (the “Common Stock”) not currently held by NEA for cash consideration of $7.18 per share (the “Transaction”).  These discussion materials (the “Materials”) were provided to, and solely for the information of, the Committee by Lincoln in connection with its consideration of a Transaction. The Materials are incomplete without reference to and should be considered in conjunction with any supplemental information provided by and discussions held with Lincoln in connection therewith.  Any defined terms used herein shall have the meanings set forth herein, even if such defined terms have been given different meanings elsewhere. The Materials are for discussion purposes only.  Lincoln expressly disclaims any and all liability which may be based on these Materials and any errors therein or omissions therefrom.  The Materials were prepared for specific persons familiar with the business and affairs of the Company and the Committee for use in a specific context and were not prepared with a view toward public disclosure or to conform with any disclosure standards under any state, federal or international securities laws or other laws, rules or regulations, and none of the Committee, Company, or Lincoln takes any responsibility for the use of the Materials by persons other than the Committee. The Materials are being provided on a confidential basis solely for the information of the Committee, other than as described in the engagement letter between Lincoln and the Company, dated July 31, 2024, and may not be disclosed, summarized, reproduced, disseminated, quoted, or otherwise referred to, in whole or in part, without Lincoln’s express prior written consent.  The Materials are necessarily based on financial, economic, market, and other conditions as in effect on, and the information available to Lincoln as of, the date of the Materials. Although subsequent developments may affect the contents of the Materials, Lincoln has not undertaken, and is under no obligation, to update, revise, or reaffirm the Materials. The Materials are not intended to provide the sole basis for evaluation of the Transaction and do not purport to contain all information that may be required to do so. The Materials do not address the underlying business decision of the Committee, the Company or any other party to approve, make any elections with respect to, proceed with or effect the Transaction. The Materials do not constitute an opinion, nor do the Materials or any opinion rendered by Lincoln constitute a recommendation to the Committee, the Company, any security holder of the Company, or any other party as to how to vote or act with respect to any matter relating to the Transaction or otherwise..  The Materials may not reflect information known to other professionals in other business areas of Lincoln and its affiliates.  The preparation of the Materials was a complex process involving quantitative and qualitative judgments and determinations with respect to the financial, comparative, and other analytic methods employed and the adaption and application of these methods to the unique facts and circumstances presented and, therefore, is not readily susceptible to partial analysis or summary description. Furthermore, Lincoln did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Each analytical technique has inherent strengths and weaknesses, and the nature of the available information may further affect the value of particular techniques. Accordingly, the analyses contained in the Materials must be considered as a whole. Selecting portions of the analyses, analytic methods and factors without considering all analyses and factors could create a misleading or incomplete view. The Materials reflect judgments and assumptions with regard to industry performance, general business, economic, regulatory, market, financial conditions, and other matters, many of which are beyond the control of the participants in the Transaction.  Any estimates of value contained in the Materials are not necessarily indicative of actual value or predictive of future results or values, which may be significantly more or less favorable.  Any analyses relating to the value of assets, businesses, or securities do not purport to be appraisals or to reflect the prices at which any assets, businesses, or securities may actually be sold.  2 
 

 CONFIDENTIAL DRAFT  Disclaimer and Confidentiality Statement (cont’d)  The Materials do not constitute a fairness opinion, solvency opinion, valuation opinion, credit rating, an analysis of the Company’s credit worthiness, as tax advice, or as accounting advice. The Materials do not address any other terms, aspects, or implications of the Transaction, or any agreements, arrangements, or understandings entered into in connection with the Transaction or otherwise. Furthermore, the Materials do not address the fairness of any portion or aspect of the Transaction to any party. In preparing the Materials, Lincoln has not conducted any physical inspection or independent appraisal or evaluation of any of the assets, properties, or liabilities (contingent or otherwise) of the Company or any other party. No company utilized in our selected public companies analysis is directly comparable to the Company.  Except as otherwise noted in the Materials, all budgets, projections, estimates, financial analyses, reports, and other information with respect to operations (including estimates of potential cost savings and expenses) reflected in the Materials have been prepared by the Company or are derived from such budgets, projections, estimates, financial analyses, reports and other information or from other sources, which involve numerous and significant subjective determinations made by management of the Company (“Management”) and/or which Management has reviewed and found reasonable. Any budgets, projections and estimates contained in the Materials may or may not be achieved and differences between projected results and those actually achieved may be material. Lincoln has relied upon representations made by the Company that any budgets, projections or estimates contained herein have been reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of Management (or, with respect to information obtained from public sources, represent reasonable estimates), and Lincoln expresses no opinion with respect to such budgets, projections, or estimates or the assumptions on which they are based.  Lincoln has assumed and relied upon the accuracy and completeness of the financial and other information provided to, discussed with or reviewed by it without (and without assuming responsibility for) independent verification of such information, makes no representation or warranty (express or implied) in respect of the accuracy or completeness of such information and has further relied upon the assurances of the Company that they are not aware of any facts or circumstances that would make such information inaccurate or misleading. In addition, Lincoln has relied upon and assumed, without independent verification, that there has been no change in the business, assets, liabilities, financial condition, results of operations, cash flows, or prospects of the Company or any other participant in the Transaction since the respective dates of the most recent information, financial or otherwise, provided to, discussed with or reviewed by Lincoln that would be material to its analyses, and that the final forms of any draft documents reviewed by Lincoln will not differ in any material respect from such draft documents.  The Materials do not constitute a commitment by Lincoln or any of its affiliates to underwrite, subscribe for or place any securities, to extend or arrange credit, or to provide any other services.  Lincoln provides mergers and acquisitions, restructuring, and other advisory services to clients, which may in the future include, one or more interested parties to the Transaction (each an “Interested Party”), for which services Lincoln may receive compensation. As of the date hereof, Lincoln has not provided and is not currently providing any other services to the Company or NEA. Although Lincoln may in the future acquire, information about one or more Interested Party or the Transaction, or that otherwise may be of interest to the Company or the Committee, Lincoln shall have no obligation to, and may not be contractually permitted to, disclose such information, or the fact that Lincoln is in possession of such information, to the Company or the Committee or to use such information on the Company’s or the Committee’s behalf.  Lincoln and our affiliates provide a range of investment banking and financial services and, in that regard, we and our affiliates may in the future provide, investment banking and other financial services to the Company, for which we and our affiliates would expect to receive compensation. In the prior two years, Lincoln has not received any fees from the Company or NEA.  THESE MATERIALS ARE NOT INTENDED TO REPRESENT NOR DO THEY REPRESENT AN OPINION BY LINCOLN.  3 
 

 CONFIDENTIAL DRAFT  Table of Contents  Section 1  Executive Summary  5  Section 2  Valuation Analysis  10  Appendix A  Supplemental Analysis and Detail  17 
 

 CONFIDENTIAL DRAFT  Executive Summary  Section 1 
 

 CONFIDENTIAL DRAFT  Executive Summary  Valuation Analysis Summary  $0.00 $2.00  Source: Management Projections  Key Valuation Metrics  WACC range  23.0% to 25.00%  Terminal Growth Rate 7.50%  6.0x to 7.0x 2026P EBITDA  of $141 million  Liquidation Preference of Series A and Series B Preferred Stock exceeds Aggregate Equity Value  Methodology  DCF:  60% OPM Volatility  DCF:  50% OPM Volatility  Selected Public Companies Analysis: 60% OPM Volatility  Selected Public Companies Analysis: 50% OPM Volatility  Intrinsic Value  Estimated Value Per Share of Common Stock  NEA Offer Price  $7.18  6  $2.71  $4.25  $3.26  $4.93  $0.00  $5.90  $8.03  $6.31  $8.49  $4.00  $6.00  $8.00  $10.00 
 

 CONFIDENTIAL DRAFT  Executive Summary  Valuation Analysis Summary  Source: Management Projections  Present value of tax savings related to $3.2 billion in federal NOLs and $3.8 billion in state NOLs  As of June 30, 2024  $100 million expected to be received in November 2024. $10 million expected to be received in June 2025, per Management  Present value of expected March 2025 settlement payment to CMS net of statutory capital and  surplus, per Management  Primarily reflects obligations resulting from Babylon Health's bankruptcy, per Management  Includes various non-operating assets, non-operating liabilities and one-time items, per Management  Based on a present value of expected future payments to acquire remaining ownership stake in  Centrum, per Management  Present value of projected after-tax income attributable to PMA noncontrolling interest, per Management  7   DCF Analysis Selected Public Companies   Low  High  Low  High  Indicated Enterprise Value Range (Before NOLs, Rounded)  $875  - $1,005  $845  - $990  Present Value of NOL Tax Benefits (1)  120  - 135  120  - 135  Concluded Enterprise Value Range  $995  - $1,140  $965  - $1,125  Cash and Cash Equivalents (2)  133  - 133  133  - 133  Short-Term Investments (2)  9  - 9  9  - 9  NEA Term Loan (2)  (95)  - (95)  (95)  - (95)  Hercules Term Loan (2)  (30)  - (30)  (30)  - (30)  Expected Remaining Net Proceeds from Molina (3)  110  - 110  110  - 110  CMS Settlement Payment (4)  (203)  - (203)  (203)  - (203)  DCE Deficit Adjustment (5)  (42)  - (42)  (42)  - (42)  Other Items (6)  (21)  - (21)  (21)  - (21)  Estimated Value of Centrum Noncontrolling Interest (7)  (68)  - (70)  (68)  - (70)  Estimated Value of PMA Noncontrolling Interest (8)  (100)  - (113)  (100)  - (113)  Equity Value Available to Holders of Preferred Stock and Common Stock  $689  - $819  $659  - $804  Implied Concluded Enterprise Value Multiples (Including NOL Tax Benefits)  2026P EBITDA  $141  7.1x  - 8.1x  6.8x  - 8.0x  2024E Revenue  2,712  0.37x  - 0.42x  0.36x  - 0.41x  Valuation Analysis Summary  ($ in millions, except per share values) 
 

 CONFIDENTIAL DRAFT  Executive Summary  Valuation Analysis Summary – Equity Allocation  See Appendix A  As of June 30, 2024  8   DCF A  Low  nalysis   High   Selected Pub  Low  lic Companies   High  Allocation of Equity Value - Option Pricing Model  Equity Value Available to Holders of Preferred Stock and Common Stock  $689  - $819  $659  - $804  Value of Common Stock: 50% Volatility  $46  - $90  $39  - $84  Fully Diluted Shares Outstanding (1)  14,243,521  - 14,243,521  14,243,521  - 14,243,521  Common Stock Per Share Value: 50% Volatility  $3.26  - $6.31  $2.71  - $5.90  Value of Common Stock: 60% Volatility  $70  - $121  $60  - $114  Fully Diluted Shares Outstanding (1)  14,243,521  - 14,243,521  14,243,521  - 14,243,521  Common Stock Per Share Value: 60% Volatility  $4.93  - $8.49  $4.25  - $8.03  Intrinsic Value Waterfall  Equity Value Available to Holders of Preferred Stock and Common Stock  $689  - $819  $659  - $804  Liquidation   Preference (2)  Series A Preferred Stock  $849  ($563)  - ($668)  ($539)  - ($656)  Series B Preferred Stock 190 (126) - (150) (121) - (147)  Equity Value Allocated to Preferred Stock  1,039  (689)  -  (819) -  (659)  -  (804)  Intrinsic Value of Common Stock  $0  -  $0  $0  -  $0  Valuation Analysis Summary  ($ in millions, except per share values) 
 

 CONFIDENTIAL DRAFT  Lincoln has assumed the following strategic alternatives that may be available to the Company:  ‒ Pursue a sale to NEA  Consider optimal timing of a limited outreach to other potential buyers  ‒ Status quo  ‒ Broad auction sale process  ‒ Divestiture  ‒ Recapitalization  Based on discussions with Management, Lincoln has assessed certain commercial risks and other considerations for the Committee’s evaluation of the timing for a limited outreach to other potential buyers:  ‒ Market chatter  ‒ VBC contract renewals  ‒ Provider partner ACO relationships  ‒ Liquidity concerns & financial position  ‒ Preferred stock overhang  ‒ Buyer appetite  In any limited outreach process, Lincoln would recommend that it contact:  Executive Summary  Strategic Alternatives  9 
 

 CONFIDENTIAL DRAFT  Valuation Analysis  Section 2 
 

 CONFIDENTIAL DRAFT  Lincoln performed a valuation of (i) the Company on an enterprise value basis and (ii) the common stock of the Company. Lincoln estimated ranges of enterprise values for the Company using each of the following valuation approaches described below assuming the Company would continue to operate as a public company:  Discounted Cash Flow Analysis (“DCF”) (Income Approach)  Present value of projected unlevered free cash flows discounted at a rate commensurate with risk  Key inputs include the projections provided to Lincoln by Management (the “Management Projections”), discount  rate, and terminal value assumptions  Captures value associated with long-term cash flow generating ability of the Company  Pro forma for taxes assuming no utilization of historical and future net operating losses (“NOLs”) and therefore excludes value of NOL tax savings  Market Approach  Selected Public Companies Analysis  ‒ “Public market valuation”  ‒ Value based on market trading multiples of selected public companies using comparisons of various attributes  (financial performance, capital requirements, geographic footprint, customer base, payor mix, etc.)  Lincoln did not consider a M&A Transactions Analysis due to the following:  ‒ Valuation multiple for M&A transactions reflects premium for control;  ‒ Generally computed based on historical financial performance (i.e., LTM EBITDA), which is not meaningful for the Company;  ‒ Lack of relevant recent transactions;  ‒ Historical transactions generally involved strategic acquirers resulting in implied valuation multiples inclusive of synergies  Valuation Analysis  Methodology  11 
 

 CONFIDENTIAL DRAFT  Valuation Analysis  Methodology (continued)  Lincoln then estimated ranges of aggregate equity value available to the holders of Common Stock and the Company’s Series A Preferred Stock and Series B Preferred Stock (the “Preferred Stock”) by adjusting the estimated enterprise value ranges for cash and cash equivalents, non- operating assets, debt and debt-like items, non-operating liabilities and the estimated value of noncontrolling interests.  Given that the aggregate liquidation preference of the Preferred Stock exceed the estimated ranges of aggregate equity value available to the holders of Common Stock and the Preferred Stock, Lincoln estimated the value of the Common Stock using an option pricing model (“OPM”). This valuation methodology is based on the principles of option pricing theory, whereby the Series A Preferred Stock, Series B Preferred Stock and Common Stock are each modeled as a call option with a unique claim on the estimated ranges of aggregate equity value available to the holders of Common Stock and the Preferred Stock. The economic characteristics of each security define these claims. The resulting option claims, in combination, depicts the sharing of proceeds between different securities upon a liquidity event. The result is an allocation of the aggregate equity value to each class of security. The effect in this case is an allocation of positive value to the Common Stock which represents “option value” despite the Common Stock having zero intrinsic value.  The key inputs of OPM include: (i) initial value of an underlying asset; (ii) exercise price; (iii) volatility; (iv) time to expiration; and (v) risk free rate. Lincoln utilized a term of approximately 1.00 year assuming an event that could trigger a sale or recapitalization on or before July 31, 2025. Lincoln selected a range of levered equity volatilities from 50% to 60% which was based on its review of unlevered volatiles of the selected public companies which were re-levered based on the Company’s current capital structure for the OPM.  Lincoln divided the resulting Common Stock value ranges by fully diluted shares outstanding to derive per share value ranges of the Common Stock.  Additionally, Lincoln calculated the intrinsic value of the Common Stock to be $0.  12 
 

 CONFIDENTIAL DRAFT  Valuation Analysis  DCF Analysis - Summary  Note: 2025P to 2027P pro forma share-based compensation expense provided by Management Source: Management Projections  (1) Normalizes depreciation and amortization expenses equal to capital expenditures   Management Projections   FY Ending December 31, 2023A 2024E 2025P 2026P 2027P  Normalized  Terminal (1)  Total Revenue  $1,161  $949  $1,719  $2,712  $3,659  $3,659  % Growth  54.5%  (18.2%)  81.1%  57.7%  34.9%  Adjusted EBITDA Excl. SBC  ($8)  $26  $87  $193  $332  Share-based Compensation Expense   (84)  (71)  (46)  (52)  (59)  Adjusted EBITDA  ($92)  ($45)  $42  $141  $273  $273  % Margin  (7.9%)  (4.8%)  2.4%  5.2%  7.5%  7.5%  % Growth  NMF  NMF  NMF  NMF  93.6%  7/24 - 12/24  Adjusted EBIT  ($5)  $24  $130  $252  $273  Pro Forma Taxes @ 23.5%  0  (6)  (30)  (59)  (64)  NOPAT  ($5)  $18  $99  $193  $209  Depreciation & Amortization  ($8)  $18  $11  $22  $0  Capital Expenditures  0  0  0  0  0  Other Operating Cash Flows  10  (0)  (1)  (1)  (1)  (Increase) Decrease in Net Working Capital  0  0  0  0  0  Unlevered Free Cash Flow  ($3)  $36  $110  $213  $208  % Growth  Enterprise Value  Low  NA  203.7%  High  94.2%  Weighted Average Cost of Capital (WACC)  25.00%  -  23.00%  Terminal Growth Rate (TGR)  7.50%  -  7.50%  Present Value of Discrete Cash Flows  $209  -  $218  Present Value of Terminal Value  666  -  788  Indicated Enterprise Value (Rounded)  $875  -  $1,005   Implied Enterprise Value Multiples   2026P EBITDA  $141  6.2x  - 7.1x  2024E Revenue  2,712  0.32x  - 0.37x  13  Discounted Cash Flow Analysis Summary  ($ in millions) 
 

 CONFIDENTIAL DRAFT  Valuation Analysis  Selected Public Companies Analysis – Summary  Lincoln considered public companies that operate as managed care organizations (“MCOs”) and value-based care providers (“VBCs”).  Lincoln’s selected multiples for the Company were based on a comparative analysis that considered, among other things, certain quantitative and qualitative factors including the following: relative size, historical and projected growth and profitability, capital intensity, geographic presence, customer mix, payor mix, and other financial performance metrics.  Considering the factors above, Lincoln selected a multiple range of 6.0x to 7.0x on 2026P EBITDA.  None of the selected public companies is identical to the Company.  Lincoln does not have access to non-public information regarding those companies.  Source: S&P Capital IQ, company filings, Management Projections  14  Selected Public Companies   Median Selected Multiples Financial Enterprise Value   Enterprise Value Multiple  Low  - High  MCO  VBC  Consolidated  Low  - High  Statistic  Low  - High  2026P EBITDA  4.7x  - 35.6x  7.7x  17.0x  8.3x  6.0x  - 7.0x  $141  $847  - $988  Selected Public Companies Analysis Summary  ($ in millions)  Indicated Enterprise Value Range (Rounded) $845 - $990   Implied Enterprise Value Multiples   2025P EBITDA  8.1x  - 46.3x  8.8x  28.1x  9.9x  $42  20.1x  - 23.6x  2026P EBITDA  4.7x  - 35.6x  7.7x  17.0x  8.3x  141  6.0x  - 7.0x  2024E Revenue  0.26x  - 1.45x  0.51x  0.77x  0.51x  949  0.89x  - 1.04x 
 

 CONFIDENTIAL DRAFT  Valuation Analysis  Selected Public Companies – Financial Metrics  Source: S&P Capital IQ, company filings, Management Projections  (1) 2024E to 2026P based on Management Projections  15  Company Name  2023A Financial Statistics  Revenue Growth  EBITDA Margin  Revenue EBITDA  2023A  2024E 2025P  2026P  2023A  2024E 2025P  2026P  MCOs  Alignment Healthcare, Inc.  $1,824  ($102)  27.2%  38.6%  22.3%  20.7%  (5.6%)  (3.7%)  (2.4%)  (1.8%)  Centene Corporation  153,999  5,845  6.5%  0.2%  2.9%  3.7%  3.8%  2.9%  3.0%  3.2%  Clover Health Investments, Corp.  2,034  (186)  (41.5%)  (34.0%)  3.1%  6.1%  (9.1%)  (6.1%)  (5.4%)  (5.2%)  Elevance Health, Inc.  170,209  12,118  9.3%  1.3%  6.6%  7.5%  7.1%  7.7%  7.9%  8.0%  Humana Inc.  106,374  5,712  14.5%  7.6%  0.9%  5.9%  5.4%  3.5%  4.0%  4.4%  Molina Healthcare, Inc.  33,003  1,751  6.1%  20.4%  7.5%  8.1%  5.3%  5.1%  5.3%  5.5%  Oscar Health, Inc.  5,863  (205)  47.9%  47.9%  25.6%  18.0%  (3.5%)  0.8%  2.4%  4.1%  The Cigna Group  195,322  11,980  8.1%  20.6%  4.5%  6.2%  6.1%  5.7%  5.9%  6.0%  UnitedHealth Group Incorporated  371,622  36,330  14.6%  7.5%  7.8%  7.4%  9.8%  9.8%  10.2%  10.4%  Mean - MCOs  $115,583  $8,138  10.3%  12.2%  9.0%  9.3%  2.1%  2.8%  3.4%  3.8%  Median - MCOs  106,374  5,712  9.3%  7.6%  6.6%  7.4%  5.3%  3.5%  4.0%  4.4%  VBCs  agilon health, inc.  $4,316  ($164)  80.7%  42.8%  21.7%  18.6%  (3.8%)  (1.8%)  (0.6%)  0.0%  Astrana Health, Inc.  1,387  125  21.2%  27.0%  22.4%  19.3%  9.0%  8.8%  8.3%  8.3%  CareMax, Inc.  751  (74)  19.0%  14.0%  24.4%  17.2%  (9.8%)  (6.3%)  (1.4%)  1.8%  InnovAge Holding Corp.  688  (6)  (1.5%)  10.7%  13.4%  NA  (0.9%)  1.7%  4.8%  NA  P3 Health Partners Inc.  1,266  (91)  20.7%  20.2%  14.0%  NA  (7.2%)  (0.3%)  0.7%  NA  Privia Health Group, Inc.  1,658  35  22.2%  0.6%  12.2%  13.8%  2.1%  2.1%  2.8%  3.2%  Mean - VBCs  $1,678  ($29)  27.0%  19.2%  18.0%  17.2%  (1.8%)  0.7%  2.4%  3.3%  Median - VBCs  1,327  (40)  20.9%  17.1%  17.9%  17.9%  (2.4%)  0.7%  1.7%  2.5%  Mean - Consolidated  $70,021  $4,871  17.0%  15.0%  12.6%  11.7%  0.6%  2.0%  3.0%  3.7%  Median - Consolidated  4,316  35  14.6%  14.0%  12.2%  8.1%  2.1%  2.1%  3.0%  4.1%  NeueHealth, Inc. (1)  $1,161  ($92)  54.5%  (18.2%)  81.1%  57.7%  (7.9%)  (4.8%)  2.4%  5.2%  Data Updated Through: July 31, 2024  Selected Public Companies Analysis - Financial Metrics  ($ in millions) 
 

 CONFIDENTIAL DRAFT  Valuation Analysis  Selected Public Companies – Valuation Multiples  Source: S&P Capital IQ, company filings  Enterprise Value = Market Capitalization + Management Equity + Debt + Preferred Stock + Non-Controlling Interest – Cash & Equivalents – Net Non-Operating Assets  16   EV as a Multiple of   Stock Price as  % of 52  Market  Enterprise  2024  2025  2026  2024  Company Name  of 7/31/24  Week High  Capitalization  Value  EBITDA  EBITDA  EBITDA  Revenue  MCOs  Alignment Healthcare, Inc.  $8.74  86.0%  $1,875  $1,852  NMF  NMF  NMF  0.73x  Centene Corporation  76.92  94.5%  41,036  39,786  9.0x  8.4x  7.6x  0.26x  Clover Health Investments, Corp.  1.91  97.0%  1,114  803  NMF  NMF  NMF  0.60x  Elevance Health, Inc.  532.03  95.8%  124,473  128,036  9.7x  8.8x  8.1x  0.74x  Humana Inc.  361.61  68.2%  43,811  45,969  11.4x  9.9x  8.5x  0.40x  Molina Healthcare, Inc.  341.27  80.5%  20,321  18,190  9.0x  8.1x  7.1x  0.46x  Oscar Health, Inc.  17.68  75.4%  4,935  2,452  36.7x  9.3x  4.7x  0.28x  The Cigna Group  348.67  95.3%  100,759  120,928  9.0x  8.4x  7.7x  0.51x  UnitedHealth Group Incorporated  576.16  99.1%  537,973  577,491  14.8x  13.2x  11.9x  1.45x  Mean - MCOs  88.0%  $97,366  $103,945  14.2x  9.4x  8.0x  0.60x  Median - MCOs  94.5%  41,036  39,786  9.7x  8.8x  7.7x  0.51x  VBCs  agilon health, inc.  $6.89  32.0%  $2,903  $2,570  NMF  NMF  NMF  0.42x  Astrana Health, Inc.  52.46  96.7%  2,392  2,256  14.6x  12.6x  10.6x  1.28x  CareMax, Inc.  6.22  7.2%  24  378  NMF  NMF  17.0x  0.44x  InnovAge Holding Corp.  6.28  81.2%  892  882  66.0x  20.2x  NA  1.11x  P3 Health Partners Inc.  0.63  21.4%  105  442  NMF  36.0x  NA  0.29x  Privia Health Group, Inc.  20.74  74.1%  2,717  2,412  68.9x  46.3x  35.6x  1.45x  Mean - VBCs  Median - VBCs  52.1%  53.0%  $1,506  1,642  $1,490  1,569  49.8x  66.0x  28.8x  28.1x  21.1x  17.0x  0.83x  0.77x  Mean - Consolidated  73.6%  $59,022  $62,963  24.9x  16.5x  11.9x  0.69x  Median - Consolidated  81.2%  2,903  2,452  13.0x  9.9x  8.3x  0.51x  Data Updated Through: July 31, 2024  Selected Public Companies Analysis - Valuation Multiples  ($ in millions, except share count and per share amounts) 
 

 Supplemental Analysis and Detail  Appendix A 
 

 CONFIDENTIAL DRAFT  Supplemental Analysis and Detail  Premiums Paid Analysis  To identify the relevant transactions in the Premiums Paid Analysis, Lincoln screened S&P Capital IQ using the following criteria:  Total Transaction Value ($USDmm, Historical rate): Is between 500 and 2,500  Target Market Cap 1-Day Prior ($USDmm, Historical rate): is greater than 1  M&A Closed Date: [7/31/2019-7/31/2024]  Geographic Locations (Target/Issuer): United States of America  Percent Sought (%): is greater than 49  Offer per share ($USD, Historical rate): is greater than 0.01 – resulted in All Deals (n = 259)  Industry Classifications (Target/Issuer): Health Care (Primary)  Industry Classifications (Target/Issuer): NOT (Pharmaceuticals, Biotechnology and Life Sciences – for Health Care Deals (n = 19)  Source: S&P Capital IQ  Note: Excludes transactions involving special purpose acquisition corporations; Reflects calendar day trading metrics  18  25th Percentile  20%  22%  29%  Median  29%  31%  43%  75th Percentile  46%  45%  57%  NEUE- Stock Price as of July 31, 2024  $6.53  $5.21  $5.48  NEA Offer Price @ $7.18  10.0%  37.8%  31.0%  Percent Premiums Paid Per Share   Premium to 1-Day 7-Day 30-Day   Price Price VWAP   All Deals (n = 259)  31%  $7.18  10%  25th Percentile  14%  16%  17%  35%  7.40  13%  Median  30%  33%  39%  40%  7.67  18%  75th Percentile  51%  56%  64%  45%  7.95  22%  50%  8.22  26%  Health Care Deals (Excl. Pharmaceuticals, Biotechnology and Life Sciences) (n = 19) 55% 8.50 30%  Premium to  ($5.48)  30-Day VWAP Implied Offer  Price  Premium to 7/30 Closing Price ($6.53)  60%  65%  8.77  9.04  34%  38% 
 

 CONFIDENTIAL DRAFT  Share Price  NeueHealth, Inc. (NYSE:NEUE) - Historical Trading Summary  In USD  Supplemental Analysis and Detail  Historical NEUE Stock Trading Chart  0.00  0.40  0.80  1.20  1.60  2.00  $0  $200  $400  $600  $800  $1,000  Sep-21  Dec-21  Mar-22  Jun-22  Sep-22  Dec-22  Mar-23  Jun-23  Sep-23  Dec-23  Mar-24  Jun-24  Volume (millions)  Volume  Price  (1)  Source: S&P Capital IQ  (1) ~ 5.77 million shares of daily trading volume on May 26, 2023  Note: The graph and table above reflects the pricing and volume of NeueHealth’s equity listing under the ticker symbol “NEUE” on the NYSE and is pro forma for the 1-for-80 reverse stock split effective May 22, 2023  19  Stock Price as of July 31, 2024  $6.53  One-Week Average  6,908  Two -Week Average  6,088  Stock Price as of July 31, 2023  12.64  % of Shares Outstanding  0.1%  % of Shares Outstanding  0.1%  Stock Price as of July 31, 2022  134.40  % of Float  0.2%  % of Float  0.2%  10-Day Volume Weighted Average Price ("VWAP")  $5.92  One-Month Average  23,964  Six-Month Average  15,607  30-Day VWAP  5.48  % of Shares Outstanding  0.3%  % of Shares Outstanding  0.2%  60-Day VWAP  5.48  % of Float  0.7%  % of Float  0.5%  90-Day VWAP  5.68  52-Week Average Closing Price  $7.40   Equity Analyst Coverage   52-Week High Closing Price  17.58  Firm Date Price Target Rating  52-Week Low Closing Price  5.01  RBC Capital Markets 5/29/2024 $8.00 Hold  104-Week Average Closing Price  $32.39  104-Week High Closing Price  164.00  104-Week Low Closing Price  5.01   NeueHealth, Inc. - Common Stock Overview    NeueHealth, Inc. - Historical Daily Trading Volume  
 

 CONFIDENTIAL DRAFT  Supplemental Analysis and Detail  Equity Capitalization Table  Source: Management O/S = Outstanding ITM = In-the-money  (1) Reflects weighted average strike price for stock options  20  Fully Diluted  ITM  Strike Price /  Conversion  Shares O/S  Shares O/S  Price (1)  Common Stock  8,279,173  8,279,173  N/A  RSUs and PSUs  3,163,424  3,163,424  N/A  Stock Options  534,229  37  $133.50  Series A Preferred Stock  3,188,294  0  $283.19  Series B Preferred Stock  2,053,194  0  $98.68  Warrants  2,800,887  2,800,887  $0.01  Total  20,019,201  14,243,521   Equity Capitalization Table  
 


 CONFIDENTIAL DRAFT  Supplemental Analysis and Detail  Debt and Preferred Stock Capitalization Table  Source: Management  Interest rate consists of 9.65% cash and 2.50% PIK  Maturity date assumed to be 91 days after the Hercules Term Loan maturity date Note: Balances as of June 30, 2024  21   Pricing and Term   Maturity Interest Security Date Rate Feature  Current Balance  Hercules Term Loan (1)  May. '28  12.15%  $30  NEA Debt (2)  Aug. '28  15.00%  95  Total Debt  $125  Series A Preferred Stock  Perpetual  5.00%  Convertible  849  Series B Preferred Stock  Perpetual  5.00%  Convertible  190  Total Debt and Preferred Stock  $1,166  Cash and Cash Equivalents  (133)  Short-Term Investments  (9)  Net Debt and Preferred Stock  $1,023  Debt and Preferred Stock Capitalization Table  ($ in millions) 

Exhibit (c)(3)
 CONFIDENTIAL  Project Green Discussion Materials  August 5, 2024 
 

 CONFIDENTIAL  Disclaimer and Confidentiality Statement  2  Lincoln International LLC (“Lincoln”, “us”, or “we”) has been retained by the special committee (the “Committee”) of the board of directors (the “Board”) of NeueHealth, Inc. (collectively with its subsidiaries and affiliates, the “Company”) to act as its financial advisor in connection with a possible Transaction (as defined herein) involving the purchase by investment funds affiliated with New Enterprise Associates, Inc. (collectively, “NEA”) of the common stock of the Company (the “Common Stock”) not currently held by NEA for cash consideration of $7.18 per share (the “Transaction”).  These discussion materials (the “Materials”) were provided to, and solely for the information of, the Committee by Lincoln in connection with its consideration of a Transaction. The Materials are incomplete without reference to and should be considered in conjunction with any supplemental information provided by and discussions held with Lincoln in connection therewith.  Any defined terms used herein shall have the meanings set forth herein, even if such defined terms have been given different meanings elsewhere. The Materials are for discussion purposes only.  Lincoln expressly disclaims any and all liability which may be based on these Materials and any errors therein or omissions therefrom.  The Materials were prepared for specific persons familiar with the business and affairs of the Company and the Committee for use in a specific context and were not prepared with a view toward public disclosure or to conform with any disclosure standards under any state, federal or international securities laws or other laws, rules or regulations, and none of the Committee, Company, or Lincoln takes any responsibility for the use of the Materials by persons other than the Committee. The Materials are being provided on a confidential basis solely for the information of the Committee, other than as described in the engagement letter between Lincoln and the Company, dated July 31, 2024, and may not be disclosed, summarized, reproduced, disseminated, quoted, or otherwise referred to, in whole or in part, without Lincoln’s express prior written consent.  The Materials are necessarily based on financial, economic, market, and other conditions as in effect on, and the information available to Lincoln as of, the date of the Materials. Although subsequent developments may affect the contents of the Materials, Lincoln has not undertaken, and is under no obligation, to update, revise, or reaffirm the Materials. The Materials are not intended to provide the sole basis for evaluation of the Transaction and do not purport to contain all information that may be required to do so. The Materials do not address the underlying business decision of the Committee, the Company or any other party to approve, make any elections with respect to, proceed with or effect the Transaction. The Materials do not constitute an opinion, nor do the Materials or any opinion rendered by Lincoln constitute a recommendation to the Committee, the Company, any security holder of the Company, or any other party as to how to vote or act with respect to any matter relating to the Transaction or otherwise..  The Materials may not reflect information known to other professionals in other business areas of Lincoln and its affiliates.  The preparation of the Materials was a complex process involving quantitative and qualitative judgments and determinations with respect to the financial, comparative, and other analytic methods employed and the adaption and application of these methods to the unique facts and circumstances presented and, therefore, is not readily susceptible to partial analysis or summary description. Furthermore, Lincoln did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Each analytical technique has inherent strengths and weaknesses, and the nature of the available information may further affect the value of particular techniques. Accordingly, the analyses contained in the Materials must be considered as a whole. Selecting portions of the analyses, analytic methods and factors without considering all analyses and factors could create a misleading or incomplete view. The Materials reflect judgments and assumptions with regard to industry performance, general business, economic, regulatory, market, financial conditions, and other matters, many of which are beyond the control of the participants in the Transaction.  Any estimates of value contained in the Materials are not necessarily indicative of actual value or predictive of future results or values, which may be significantly more or less favorable.  Any analyses relating to the value of assets, businesses, or securities do not purport to be appraisals or to reflect the prices at which any assets, businesses, or securities may actually be sold. 
 

 CONFIDENTIAL  Disclaimer and Confidentiality Statement (cont’d)  3  The Materials do not constitute a fairness opinion, solvency opinion, valuation opinion, credit rating, an analysis of the Company’s credit worthiness, as tax advice, or as accounting advice. The Materials do not address any other terms, aspects, or implications of the Transaction, or any agreements, arrangements, or understandings entered into in connection with the Transaction or otherwise. Furthermore, the Materials do not address the fairness of any portion or aspect of the Transaction to any party. In preparing the Materials, Lincoln has not conducted any physical inspection or independent appraisal or evaluation of any of the assets, properties, or liabilities (contingent or otherwise) of the Company or any other party. No company utilized in our selected public companies analysis is directly comparable to the Company.  Except as otherwise noted in the Materials, all budgets, projections, estimates, financial analyses, reports, and other information with respect to operations (including estimates of potential cost savings and expenses) reflected in the Materials have been prepared by the Company or are derived from such budgets, projections, estimates, financial analyses, reports and other information or from other sources, which involve numerous and significant subjective determinations made by management of the Company (“Management”) and/or which Management has reviewed and found reasonable. Any budgets, projections and estimates contained in the Materials may or may not be achieved and differences between projected results and those actually achieved may be material. Lincoln has relied upon representations made by the Company that any budgets, projections or estimates contained herein have been reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of Management (or, with respect to information obtained from public sources, represent reasonable estimates), and Lincoln expresses no opinion with respect to such budgets, projections, or estimates or the assumptions on which they are based.  Lincoln has assumed and relied upon the accuracy and completeness of the financial and other information provided to, discussed with or reviewed by it without (and without assuming responsibility for) independent verification of such information, makes no representation or warranty (express or implied) in respect of the accuracy or completeness of such information and has further relied upon the assurances of the Company that they are not aware of any facts or circumstances that would make such information inaccurate or misleading. In addition, Lincoln has relied upon and assumed, without independent verification, that there has been no change in the business, assets, liabilities, financial condition, results of operations, cash flows, or prospects of the Company or any other participant in the Transaction since the respective dates of the most recent information, financial or otherwise, provided to, discussed with or reviewed by Lincoln that would be material to its analyses, and that the final forms of any draft documents reviewed by Lincoln will not differ in any material respect from such draft documents.  The Materials do not constitute a commitment by Lincoln or any of its affiliates to underwrite, subscribe for or place any securities, to extend or arrange credit, or to provide any other services.  Lincoln provides mergers and acquisitions, restructuring, and other advisory services to clients, which may in the future include, one or more interested parties to the Transaction (each an “Interested Party”), for which services Lincoln may receive compensation. As of the date hereof, Lincoln has not provided and is not currently providing any other services to the Company or NEA. Although Lincoln may in the future acquire, information about one or more Interested Party or the Transaction, or that otherwise may be of interest to the Company or the Committee, Lincoln shall have no obligation to, and may not be contractually permitted to, disclose such information, or the fact that Lincoln is in possession of such information, to the Company or the Committee or to use such information on the Company’s or the Committee’s behalf.  Lincoln and our affiliates provide a range of investment banking and financial services and, in that regard, we and our affiliates may in the future provide, investment banking and other financial services to the Company, for which we and our affiliates would expect to receive compensation. In the prior two years, Lincoln has not received any fees from the Company or NEA.  THESE MATERIALS ARE NOT INTENDED TO REPRESENT NOR DO THEY REPRESENT AN OPINION BY LINCOLN. 
 

 CONFIDENTIAL  Premiums Paid Analysis  Aggregate and Industry  To identify the relevant transactions in the Premiums Paid Analysis, Lincoln screened S&P Capital IQ using the following criteria:  Total Transaction Value ($USDmm, Historical rate): Is between 500 and 2,500  Target Market Cap 1-Day Prior ($USDmm, Historical rate): is greater than 1  M&A Closed Date: [7/31/2019-7/31/2024]  Geographic Locations (Target/Issuer): United States of America  Percent Sought (%): is greater than 49  Offer per share ($USD, Historical rate): is greater than 0.01 – resulted in All Deals (n = 260)  Industry Classifications (Target/Issuer): Health Care (Primary)  Industry Classifications (Target/Issuer): NOT (Pharmaceuticals, Biotechnology and Life Sciences) – for Health Care Deals (n = 19)  Percent Premiums Paid Per Share   Premium to 1-Day 7-Day 30-Day   Price Price VWAP   All Deals (n = 260)  25th Percentile  14%  16%  15%  Premium to 30-Day VWAP ($5.58)  Source: S&P Capital IQ  Note: Excludes transactions involving special purpose acquisition corporations; Reflects calendar day trading metrics  4  Implied Offer Price  Premium to 8/2 Closing Price ($6.22)  29%  35%  $7.18 7.54  15%  21%  Median  30%  30%  32%  40%  7.82  26%  75th Percentile  51%  54%  56%  45%  8.10  30%  50%  8.38  35%  Health Care Deals (Excl. Pharmaceuticals, Biotechnology and Life Sciences) (n = 19)  55%  8.65  39%  25th Percentile  20%  23%  25%  60%  8.93  44%  Median  29%  32%  34%  65%  9.21  48%  75th Percentile  46%  45%  42%  Closing Price as of:  8/2/2024  7/26/2024  NEUE  $6.22  $6.03  $5.58  NEA Offer Price @ $7.18  15%  19%  29% 
 

 CONFIDENTIAL  Premiums Paid Analysis  Affiliate Party Take Private Transactions  Case Study  Lincoln viewed the take-private transaction of the Tribune Publishing Company (“Tribune”) to be a relevant transaction in benchmarking the observed premiums paid.  In November 2019, Alden Global Capital (“Alden”), a financial buyer, acquired a ~25.2% stake in Tribune for ~$120 million. Alden amended the original agreement and increased its stake to ~31.6% in July 2020.  Alden acquired the remaining 68.4% stake in Tribune for ~$360  million in May 2021.  To identify the relevant transactions in the Premiums Paid Analysis, Lincoln screened S&P Capital IQ using the following criteria:  Total Transaction Value ($USDmm, Historical rate): Is between 500 and 2,500  Target Market Cap 1-Day Prior ($USDmm, Historical rate): is greater than 1  M&A Closed Date: [7/31/2019-7/31/2024]  Geographic Locations (Target/Issuer): United States of America  Merger / Acquisition Features: Majority Shareholder Purchasing Remaining Shares OR Minority Shareholder Purchasing Remaining Shares  Source: S&P Capital IQ  Note: Excludes transactions involving special purpose acquisition corporations; Reflects calendar day trading metrics  5  Percent Premiums Paid Per Share  Premium to  1-Day 7-Day 30-Day  Price Price VWAP  Affiliate Deals (n = 16)  25th Percentile  12%  10%  11%  Median  32%  29%  29%  75th Percentile  45%  47%  48%  Tribune Publishing Company  45%  42%  41%  Closing Price as of:  8/2/2024  7/26/2024  NEUE  $6.22  $6.03  $5.58  NEA Offer Price @ $7.18  15%  19%  29% 
 

 CONFIDENTIAL  NeueHealth, Inc. (NYSE:NEUE) - Historical Trading Summary  In USD  Historical NEUE Stock Trading Chart  0.00  0.40  0.80  1.20  1.60  2.00  $0  $200  $400  $600  $800  $1,000  Sep-21  Dec-21  Mar-22  Jun-22  Sep-22  Dec-22  Mar-23  Jun-23  Sep-23  Dec-23  Mar-24  Jun-24  Volume (millions)  Share Price  Volume  Price  (1)  Source: S&P Capital IQ  (1) ~ 5.77 million shares of daily trading volume on May 26, 2023  Note: The graph and table above reflects the pricing and volume of NeueHealth’s equity listing under the ticker symbol “NEUE” on the NYSE and is pro forma for the 1-for-80 reverse stock split effective May 22, 2023  Stock Price as of August 2, 2024  $6.22  One-Week Average  6,078  Two -Week Average  6,443  Stock Price as of August 2, 2023  13.42  % of Shares Outstanding  0.1%  % of Shares Outstanding  0.1%  Stock Price as of August 2, 2022  154.40  % of Float  0.2%  % of Float  0.2%  10-Day Volume Weighted Average Price ("VWAP")  $6.12  One-Month Average  22,858  Six-Month Average  14,134  30-Day VWAP  5.58  % of Shares Outstanding  0.3%  % of Shares Outstanding  0.2%  60-Day VWAP  5.53  % of Float  0.7%  % of Float  0.4%  90-Day VWAP  5.69  52-Week Average Closing Price  $7.35   Equity Analyst Coverage   52-Week High Closing Price  17.58  Firm Date Price Target Rating  52-Week Low Closing Price  5.01  RBC Capital Markets 5/29/2024 $8.00 Hold  104-Week Average Closing Price  $32.07  104-Week High Closing Price  164.00  104-Week Low Closing Price  5.01   NeueHealth, Inc. - Common Stock Overview    NeueHealth, Inc. - Historical Daily Trading Volume   6 
 

Exhibit (c)(4)

 CONFIDENTIAL  DRAFT  Project Green Discussion Materials  August 16, 2024 
 

 CONFIDENTIAL  Disclaimer and Confidentiality Statement  2  Lincoln International LLC (“Lincoln”, “us”, or “we”) has been retained by the special committee (the “Committee”) of the board of directors (the “Board”) of NeueHealth, Inc. (collectively with its subsidiaries and affiliates, the “Company”) to act as its financial advisor in connection with a possible Transaction (as defined herein) involving the purchase by investment funds affiliated with New Enterprise Associates, Inc. (collectively, “NEA”) of the common stock of the Company (the “Common Stock”) not currently held by NEA for cash consideration of $7.18 per share (the “Transaction”).  These discussion materials (the “Materials”) were provided to, and solely for the information of, the Committee by Lincoln in connection with its consideration of a Transaction. The Materials are incomplete without reference to and should be considered in conjunction with any supplemental information provided by and discussions held with Lincoln in connection therewith.  Any defined terms used herein shall have the meanings set forth herein, even if such defined terms have been given different meanings elsewhere. The Materials are for discussion purposes only.  Lincoln expressly disclaims any and all liability which may be based on these Materials and any errors therein or omissions therefrom.  The Materials were prepared for specific persons familiar with the business and affairs of the Company and the Committee for use in a specific context and were not prepared with a view toward public disclosure or to conform with any disclosure standards under any state, federal or international securities laws or other laws, rules or regulations, and none of the Committee, Company, or Lincoln takes any responsibility for the use of the Materials by persons other than the Committee. The Materials are being provided on a confidential basis solely for the information of the Committee, other than as described in the engagement letter between Lincoln and the Company, dated July 31, 2024, and may not be disclosed, summarized, reproduced, disseminated, quoted, or otherwise referred to, in whole or in part, without Lincoln’s express prior written consent.  The Materials are necessarily based on financial, economic, market, and other conditions as in effect on, and the information available to Lincoln as of, the date of the Materials. Although subsequent developments may affect the contents of the Materials, Lincoln has not undertaken, and is under no obligation, to update, revise, or reaffirm the Materials. The Materials are not intended to provide the sole basis for evaluation of the Transaction and do not purport to contain all information that may be required to do so. The Materials do not address the underlying business decision of the Committee, the Company or any other party to approve, make any elections with respect to, proceed with or effect the Transaction. The Materials do not constitute an opinion, nor do the Materials or any opinion rendered by Lincoln constitute a recommendation to the Committee, the Company, any security holder of the Company, or any other party as to how to vote or act with respect to any matter relating to the Transaction or otherwise..  The Materials may not reflect information known to other professionals in other business areas of Lincoln and its affiliates.  The preparation of the Materials was a complex process involving quantitative and qualitative judgments and determinations with respect to the financial, comparative, and other analytic methods employed and the adaption and application of these methods to the unique facts and circumstances presented and, therefore, is not readily susceptible to partial analysis or summary description. Furthermore, Lincoln did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Each analytical technique has inherent strengths and weaknesses, and the nature of the available information may further affect the value of particular techniques. Accordingly, the analyses contained in the Materials must be considered as a whole. Selecting portions of the analyses, analytic methods and factors without considering all analyses and factors could create a misleading or incomplete view. The Materials reflect judgments and assumptions with regard to industry performance, general business, economic, regulatory, market, financial conditions, and other matters, many of which are beyond the control of the participants in the Transaction.  Any estimates of value contained in the Materials are not necessarily indicative of actual value or predictive of future results or values, which may be significantly more or less favorable.  Any analyses relating to the value of assets, businesses, or securities do not purport to be appraisals or to reflect the prices at which any assets, businesses, or securities may actually be sold. 
 

 CONFIDENTIAL  Disclaimer and Confidentiality Statement (cont’d)  2  The Materials do not constitute a fairness opinion, solvency opinion, valuation opinion, credit rating, an analysis of the Company’s credit worthiness, as tax advice, or as accounting advice. The Materials do not address any other terms, aspects, or implications of the Transaction, or any agreements, arrangements, or understandings entered into in connection with the Transaction or otherwise. Furthermore, the Materials do not address the fairness of any portion or aspect of the Transaction to any party. In preparing the Materials, Lincoln has not conducted any physical inspection or independent appraisal or evaluation of any of the assets, properties, or liabilities (contingent or otherwise) of the Company or any other party. No company utilized in our selected public companies analysis is directly comparable to the Company.  Except as otherwise noted in the Materials, all budgets, projections, estimates, financial analyses, reports, and other information with respect to operations (including estimates of potential cost savings and expenses) reflected in the Materials have been prepared by the Company or are derived from such budgets, projections, estimates, financial analyses, reports and other information or from other sources, which involve numerous and significant subjective determinations made by management of the Company (“Management”) and/or which Management has reviewed and found reasonable. Any budgets, projections and estimates contained in the Materials may or may not be achieved and differences between projected results and those actually achieved may be material. Lincoln has relied upon representations made by the Company that any budgets, projections or estimates contained herein have been reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of Management (or, with respect to information obtained from public sources, represent reasonable estimates), and Lincoln expresses no opinion with respect to such budgets, projections, or estimates or the assumptions on which they are based.  Lincoln has assumed and relied upon the accuracy and completeness of the financial and other information provided to, discussed with or reviewed by it without (and without assuming responsibility for) independent verification of such information, makes no representation or warranty (express or implied) in respect of the accuracy or completeness of such information and has further relied upon the assurances of the Company that they are not aware of any facts or circumstances that would make such information inaccurate or misleading. In addition, Lincoln has relied upon and assumed, without independent verification, that there has been no change in the business, assets, liabilities, financial condition, results of operations, cash flows, or prospects of the Company or any other participant in the Transaction since the respective dates of the most recent information, financial or otherwise, provided to, discussed with or reviewed by Lincoln that would be material to its analyses, and that the final forms of any draft documents reviewed by Lincoln will not differ in any material respect from such draft documents.  The Materials do not constitute a commitment by Lincoln or any of its affiliates to underwrite, subscribe for or place any securities, to extend or arrange credit, or to provide any other services.  Lincoln provides mergers and acquisitions, restructuring, and other advisory services to clients, which may in the future include, one or more interested parties to the Transaction (each an “Interested Party”), for which services Lincoln may receive compensation. As of the date hereof, Lincoln has not provided and is not currently providing any other services to the Company or NEA. Although Lincoln may in the future acquire, information about one or more Interested Party or the Transaction, or that otherwise may be of interest to the Company or the Committee, Lincoln shall have no obligation to, and may not be contractually permitted to, disclose such information, or the fact that Lincoln is in possession of such information, to the Company or the Committee or to use such information on the Company’s or the Committee’s behalf.  Lincoln and our affiliates provide a range of investment banking and financial services and, in that regard, we and our affiliates may in the future provide, investment banking and other financial services to the Company, for which we and our affiliates would expect to receive compensation. In the prior two years, Lincoln has not received any fees from the Company or NEA.  THESE MATERIALS ARE NOT INTENDED TO REPRESENT NOR DO THEY REPRESENT AN OPINION BY LINCOLN. 
 

 CONFIDENTIAL  Premiums from $7.18 Offer Price  Source: S&P Capital IQ  Calculated based on 10 most recent trading days prior to and including reference date  Calculated based on 30 most recent trading days prior to and including reference date  June 24 August 5 August 12 August 15  36%  27%  29%  41%  34%  17%  23%  32%  25%  35%  35%  35%  0%  15%  10%  5%  20%  25%  30%  35%  40%  45%  Premiums from $7.18 Offer Price  Offer Price % Premium to Spot Price  Offer Price % Premium to 10-Day VWAP (1) Offer Price % Premium to 30-Day VWAP (2)  $5.66  2  $5.56  $5.10  $5.33  $5.82 $5.33  $5.34  $5.29 $5.36 $5.74  Initial NEA Offer Price June 24  $6.15  Counter August 5  $5.42  Current  NEA Counter  August 12 August 15 
 

 CONFIDENTIAL  Premiums Paid Analysis  Source: S&P Capital IQ  Note: Excludes transactions involving special purpose acquisition corporations  VWAP = Volume Weighted Average Price. Calculated as the sum product of Daily VWAP and Daily Volume of the number of days considered divided by the cumulative Daily Volume of the days considered using Daily VWAP and Daily Volume as reported by S&P Capital IQ  Closing price of most recent trading day prior to the announcement date  Closing price of most recent trading day seven calendar days prior to the announcement date  5  Calculated based on 10 most recent trading days prior to the announcement date  Calculated based on 30 most recent trading days prior to the announcement date  Excludes Pharmaceuticals, Biotechnology, and Life Sciences  Calculated based on 10 most recent trading days prior to and including reference date  Calculated based on 30 most recent trading days prior to and including reference date  as of:  Offer Price  Aug 12, 2024  Closing Price  Aug 15, 2024  Closing Price  Aug 08, 2024  10-Day VWAP (6)  Aug 15, 2024  30-Day VWAP (7)  Aug 15, 2024  NeueHealth, Inc.  Offer Price % Premium  $7.18  $5.10  41%  $5.16  39%  $5.42  32%  $5.34  35%   Offer Price Premium to   1-Day Price (1) 7-Day Price (2) 10-Day VWAP (3)  30-Day VWAP (4)  All Deals (n = 259)  25th Percentile  14%  15%  16%  18%  Median  30%  30%  32%  34%  75th Percentile  51%  54%  53%  57%  Healthcare Deals (5) (n = 19)  25th Percentile  20%  23%  25%  27%  Median  29%  32%  30%  32%  75th Percentile  46%  45%  43%  45%  Affiliate Deals (n = 16)  25th Percentile  12%  10%  12%  13%  Median  32%  29%  30%  28%  75th Percentile  45%  47%  51%  52% 
 

Exhibit (c)(5)
 CONFIDENTIAL  DRAFT  Project Green Discussion Materials  August 27, 2024 
 

 CONFIDENTIAL  Disclaimer and Confidentiality Statement  2  Lincoln International LLC (“Lincoln”, “us”, or “we”) has been retained by the special committee (the “Committee”) of the board of directors (the “Board”) of NeueHealth, Inc. (collectively with its subsidiaries and affiliates, the “Company”) to act as its financial advisor in connection with a possible Transaction (as defined herein) involving the purchase by investment funds affiliated with New Enterprise Associates, Inc. (collectively, “NEA”) of the common stock of the Company (the “Common Stock”) not currently held by NEA for cash consideration of $7.18 per share (the “Transaction”).  These discussion materials (the “Materials”) were provided to, and solely for the information of, the Committee by Lincoln in connection with its consideration of a Transaction. The Materials are incomplete without reference to and should be considered in conjunction with any supplemental information provided by and discussions held with Lincoln in connection therewith.  Any defined terms used herein shall have the meanings set forth herein, even if such defined terms have been given different meanings elsewhere. The Materials are for discussion purposes only.  Lincoln expressly disclaims any and all liability which may be based on these Materials and any errors therein or omissions therefrom.  The Materials were prepared for specific persons familiar with the business and affairs of the Company and the Committee for use in a specific context and were not prepared with a view toward public disclosure or to conform with any disclosure standards under any state, federal or international securities laws or other laws, rules or regulations, and none of the Committee, Company, or Lincoln takes any responsibility for the use of the Materials by persons other than the Committee. The Materials are being provided on a confidential basis solely for the information of the Committee, other than as described in the engagement letter between Lincoln and the Company, dated July 31, 2024, and may not be disclosed, summarized, reproduced, disseminated, quoted, or otherwise referred to, in whole or in part, without Lincoln’s express prior written consent.  The Materials are necessarily based on financial, economic, market, and other conditions as in effect on, and the information available to Lincoln as of, the date of the Materials. Although subsequent developments may affect the contents of the Materials, Lincoln has not undertaken, and is under no obligation, to update, revise, or reaffirm the Materials. The Materials are not intended to provide the sole basis for evaluation of the Transaction and do not purport to contain all information that may be required to do so. The Materials do not address the underlying business decision of the Committee, the Company or any other party to approve, make any elections with respect to, proceed with or effect the Transaction. The Materials do not constitute an opinion, nor do the Materials or any opinion rendered by Lincoln constitute a recommendation to the Committee, the Company, any security holder of the Company, or any other party as to how to vote or act with respect to any matter relating to the Transaction or otherwise..  The Materials may not reflect information known to other professionals in other business areas of Lincoln and its affiliates.  The preparation of the Materials was a complex process involving quantitative and qualitative judgments and determinations with respect to the financial, comparative, and other analytic methods employed and the adaption and application of these methods to the unique facts and circumstances presented and, therefore, is not readily susceptible to partial analysis or summary description. Furthermore, Lincoln did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Each analytical technique has inherent strengths and weaknesses, and the nature of the available information may further affect the value of particular techniques. Accordingly, the analyses contained in the Materials must be considered as a whole. Selecting portions of the analyses, analytic methods and factors without considering all analyses and factors could create a misleading or incomplete view. The Materials reflect judgments and assumptions with regard to industry performance, general business, economic, regulatory, market, financial conditions, and other matters, many of which are beyond the control of the participants in the Transaction.  Any estimates of value contained in the Materials are not necessarily indicative of actual value or predictive of future results or values, which may be significantly more or less favorable.  Any analyses relating to the value of assets, businesses, or securities do not purport to be appraisals or to reflect the prices at which any assets, businesses, or securities may actually be sold. 
 

 CONFIDENTIAL  Disclaimer and Confidentiality Statement (cont’d)  2  The Materials do not constitute a fairness opinion, solvency opinion, valuation opinion, credit rating, an analysis of the Company’s credit worthiness, as tax advice, or as accounting advice. The Materials do not address any other terms, aspects, or implications of the Transaction, or any agreements, arrangements, or understandings entered into in connection with the Transaction or otherwise. Furthermore, the Materials do not address the fairness of any portion or aspect of the Transaction to any party. In preparing the Materials, Lincoln has not conducted any physical inspection or independent appraisal or evaluation of any of the assets, properties, or liabilities (contingent or otherwise) of the Company or any other party. No company utilized in our selected public companies analysis is directly comparable to the Company.  Except as otherwise noted in the Materials, all budgets, projections, estimates, financial analyses, reports, and other information with respect to operations (including estimates of potential cost savings and expenses) reflected in the Materials have been prepared by the Company or are derived from such budgets, projections, estimates, financial analyses, reports and other information or from other sources, which involve numerous and significant subjective determinations made by management of the Company (“Management”) and/or which Management has reviewed and found reasonable. Any budgets, projections and estimates contained in the Materials may or may not be achieved and differences between projected results and those actually achieved may be material. Lincoln has relied upon representations made by the Company that any budgets, projections or estimates contained herein have been reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of Management (or, with respect to information obtained from public sources, represent reasonable estimates), and Lincoln expresses no opinion with respect to such budgets, projections, or estimates or the assumptions on which they are based.  Lincoln has assumed and relied upon the accuracy and completeness of the financial and other information provided to, discussed with or reviewed by it without (and without assuming responsibility for) independent verification of such information, makes no representation or warranty (express or implied) in respect of the accuracy or completeness of such information and has further relied upon the assurances of the Company that they are not aware of any facts or circumstances that would make such information inaccurate or misleading. In addition, Lincoln has relied upon and assumed, without independent verification, that there has been no change in the business, assets, liabilities, financial condition, results of operations, cash flows, or prospects of the Company or any other participant in the Transaction since the respective dates of the most recent information, financial or otherwise, provided to, discussed with or reviewed by Lincoln that would be material to its analyses, and that the final forms of any draft documents reviewed by Lincoln will not differ in any material respect from such draft documents.  The Materials do not constitute a commitment by Lincoln or any of its affiliates to underwrite, subscribe for or place any securities, to extend or arrange credit, or to provide any other services.  Lincoln provides mergers and acquisitions, restructuring, and other advisory services to clients, which may in the future include, one or more interested parties to the Transaction (each an “Interested Party”), for which services Lincoln may receive compensation. As of the date hereof, Lincoln has not provided and is not currently providing any other services to the Company or NEA. Although Lincoln may in the future acquire, information about one or more Interested Party or the Transaction, or that otherwise may be of interest to the Company or the Committee, Lincoln shall have no obligation to, and may not be contractually permitted to, disclose such information, or the fact that Lincoln is in possession of such information, to the Company or the Committee or to use such information on the Company’s or the Committee’s behalf.  Lincoln and our affiliates provide a range of investment banking and financial services and, in that regard, we and our affiliates may in the future provide, investment banking and other financial services to the Company, for which we and our affiliates would expect to receive compensation. In the prior two years, Lincoln has not received any fees from the Company or NEA.  THESE MATERIALS ARE NOT INTENDED TO REPRESENT NOR DO THEY REPRESENT AN OPINION BY LINCOLN. 
 

 CONFIDENTIAL  36%  27%  29%  41%  46%  50%  34%  17%  23%  32%  42%  43%  25%  35%  35%  35%  37%  34%  0%  10%  20%  30%  40%  50%  Offer Price % Premium to Spot Price  Offer Price % Premium to 10-Day VWAP (1)  Offer Price % Premium to 30-Day VWAP (2)  Premiums from Offer Price  Source: S&P Capital IQ  Calculated based on 10 most recent trading days prior to and including reference date  Calculated based on 30 most recent trading days prior to and including reference date  $5.29 $5.36 $5.74  $5.66 $6.15 $5.33  $5.56 $5.82 $5.33  $5.10 $5.42 $5.34  Initial NEA Offer Price June 24  Counter August 5  NEA Counter August 12  Counter August 15  $5.03 $5.17 $5.34  NEA Counter August 22  Offer Price: $7.18  Offer Price: $7.33  Current August 26  2  $4.90 $5.12 $5.47 
 

 CONFIDENTIAL  Premiums Paid Analysis  Source: S&P Capital IQ  Note: Excludes transactions involving special purpose acquisition corporations  VWAP = Volume Weighted Average Price. Calculated as the sum product of Daily VWAP and Daily Volume of the number of days considered divided by the cumulative Daily Volume of the days considered using Daily VWAP and Daily Volume as reported by S&P Capital IQ  Closing price of most recent trading day prior to the announcement date  Closing price of most recent trading day seven calendar days prior to the announcement date  Calculated based on 10 most recent trading days prior to the announcement date  Calculated based on 30 most recent trading days prior to the announcement date  Excludes Pharmaceuticals, Biotechnology, and Life Sciences  Calculated based on 10 most recent trading days prior to and including reference date  Calculated based on 30 most recent trading days prior to and including reference date  as of:  Offer Price  Aug 26, 2024  Closing Price  Aug 26, 2024  Closing Price  Aug 19, 2024  10-Day VWAP (6)  Aug 26, 2024  30-Day VWAP (7)  Aug 26, 2024  NeueHealth, Inc.  Offer Price % Premium  $7.33  $4.90  50%  $5.09  44%  $5.12  43%  $5.47  34%   Offer Price Premium to   1-Day Price (1) 7-Day Price (2) 10-Day VWAP (3)  30-Day VWAP (4)  All Deals (n = 259)  25th Percentile  14%  15%  16%  18%  Median  30%  30%  32%  34%  75th Percentile  51%  54%  53%  57%  Healthcare Deals (5) (n = 19)  25th Percentile  20%  23%  25%  27%  Median  29%  32%  30%  32%  75th Percentile  46%  45%  43%  45%  Affiliate Deals (n = 16)  25th Percentile  12%  10%  12%  13%  Median  32%  29%  30%  28%  75th Percentile  45%  47%  51%  52%  5 
 

Exhibit (c)(6)
 Project Green Discussion Materials  December 18, 2024 
 

 Disclaimer and Confidentiality Statement  Lincoln International LLC (“Lincoln”, “us”, or “we”) has been retained by the special committee (the “Special Committee”) of the board of directors (the “Board”) of NeueHealth, Inc.  (collectively with its subsidiaries and affiliates, the “Company”) to act as its financial advisor in connection with a possible Transaction (as defined herein).  These discussion materials (the “Materials”) were provided to, and solely for the information of, the Special Committee by Lincoln in connection with its consideration of a Transaction. The Materials are incomplete without reference to and should be considered in conjunction with any supplemental information provided by and discussions held with Lincoln in connection therewith.  Any defined terms used herein shall have the meanings set forth herein, even if such defined terms have been given different meanings elsewhere. The Materials are for discussion purposes only.  Lincoln expressly disclaims any and all liability which may be based on these Materials and any errors therein or omissions therefrom.  The Materials were prepared for specific persons familiar with the business and affairs of the Company and the Special Committee for use in a specific context and were not prepared with a view toward public disclosure or to conform with any disclosure standards under any state, federal or international securities laws or other laws, rules or regulations, and none of the Special Committee, Company, or Lincoln takes any responsibility for the use of the Materials by persons other than the Special Committee. The Materials are being provided on a confidential basis solely for the information of the Special Committee, other than as described in the engagement letter between Lincoln and the Company, dated July 31, 2024, and may not be disclosed, summarized, reproduced, disseminated, quoted, or otherwise referred to, in whole or in part, without Lincoln’s express prior written consent.  The Materials are necessarily based on financial, economic, market, and other conditions as in effect on, and the information available to Lincoln as of, the date of the Materials. Although subsequent developments may affect the contents of the Materials, Lincoln has not undertaken, and is under no obligation, to update, revise, or reaffirm the Materials. The Materials are not intended to provide the sole basis for evaluation of the Transaction and do not purport to contain all information that may be required to do so. The Materials do not address the underlying business decision of the Special Committee, the Company or any other party to approve, make any elections with respect to, proceed with or effect the Transaction. The Materials do not constitute an opinion, nor do the Materials or any opinion rendered by Lincoln constitute a recommendation to the Special Committee, the Company, any security holder of the Company, or any other party as to how to vote or act with respect to any matter relating to the Transaction or otherwise..  The Materials may not reflect information known to other professionals in other business areas of Lincoln and its affiliates.  The preparation of the Materials was a complex process involving quantitative and qualitative judgments and determinations with respect to the financial, comparative, and other analytic methods employed and the adaption and application of these methods to the unique facts and circumstances presented. Furthermore, Lincoln did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Each analytical technique has inherent strengths and weaknesses, and the nature of the available information may further affect the value of particular techniques. Accordingly, the analyses contained in the Materials must be considered as a whole. Selecting portions of the analyses, analytic methods and factors without considering all analyses and factors could create a misleading or incomplete view. The Materials reflect judgments and assumptions with regard to industry performance, general business, economic, regulatory, market, financial conditions, and other matters, many of which are beyond the control of the participants in the Transaction.  Any estimates of value contained in the Materials are not necessarily indicative of actual value or predictive of future results or values, which may be significantly more or less favorable.  Any analyses relating to the value of assets, businesses, or securities do not purport to be appraisals or to reflect the prices at which any assets, businesses, or securities may actually be sold.  2 
 

 Disclaimer and Confidentiality Statement (cont’d)  The Materials do not constitute a fairness opinion, solvency opinion, valuation opinion, credit rating, an analysis of the Company’s credit worthiness, tax advice, or accounting advice. The Materials do not address any other terms, aspects, or implications of the Transaction, or any agreements, arrangements, or understandings entered into in connection with the Transaction or otherwise. Furthermore, the Materials do not address the fairness of any portion or aspect of the Transaction to any party. In preparing the Materials, Lincoln has not conducted any physical inspection or independent appraisal or evaluation of any of the assets, properties, or liabilities (contingent or otherwise) of the Company or any other party. No company utilized in our selected public companies analysis is directly comparable to the Company.  Except as otherwise noted in the Materials, all budgets, projections, estimates, financial analyses, reports, and other information with respect to operations (including estimates of potential cost savings and expenses) reflected in the Materials have been prepared by the Company or are derived from such budgets, projections, estimates, financial analyses, reports and other information or from other sources, which involve numerous and significant subjective determinations made by management of the Company (“Management”) and/or which Management has reviewed and found reasonable. Any budgets, projections and estimates contained in the Materials may or may not be achieved and differences between projected results and those actually achieved may be material. Lincoln has relied upon representations made by the Company that any budgets, projections or estimates contained herein have been reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of Management (or, with respect to information obtained from public sources, represent reasonable estimates), and Lincoln expresses no opinion with respect to such budgets, projections, or estimates or the assumptions on which they are based.  Lincoln has assumed and relied upon the accuracy and completeness of the financial and other information provided to, discussed with or reviewed by it without (and without assuming responsibility for) independent verification of such information, makes no representation or warranty (express or implied) in respect of the accuracy or completeness of such information and has further relied upon the assurances of the Company that they are not aware of any facts or circumstances that would make such information inaccurate or misleading. In addition, Lincoln has relied upon and assumed, without independent verification, that there has been no change in the business, assets, liabilities, financial condition, results of operations, cash flows, or prospects of the Company or any other participant in the Transaction since the respective dates of the most recent information, financial or otherwise, provided to, discussed with or reviewed by Lincoln that would be material to its analyses, and that the final forms of any draft documents reviewed by Lincoln will not differ in any material respect from such draft documents.  The Materials do not constitute a commitment by Lincoln or any of its affiliates to underwrite, subscribe for or place any securities, to extend or arrange credit, or to provide any other services.  Lincoln provides mergers and acquisitions, restructuring, and other advisory services to clients, which may in the future include one or more interested parties to the Transaction (each an “Interested Party”), for which services Lincoln may receive compensation. As of the date hereof, Lincoln has not provided and is not currently providing any other services to the Company or New Enterprise Associates, Inc. and its affiliated funds (“NEA”). Although Lincoln may in the future acquire information about one or more Interested Party or the Transaction, or that otherwise may be of interest to the Company or the Special Committee, Lincoln shall have no obligation to, and may not be contractually permitted to, disclose such information, or the fact that Lincoln is in possession of such information, to the Company or the Special Committee or to use such information on the Company’s or the Special Committee’s behalf.  Lincoln and our affiliates provide a range of investment banking and financial services and, in that regard, we and our affiliates may in the future provide, investment banking and other financial services to the Company, for which we and our affiliates would expect to receive compensation. In the prior two years, Lincoln has not received any fees from the Company or NEA.  THESE MATERIALS ARE NOT INTENDED TO REPRESENT NOR DO THEY REPRESENT AN OPINION BY LINCOLN.  3 
 

 Table of Contents  Section 1  Executive Summary  5  Section 2  Valuation Analysis  10  Appendix A  Supplemental Analysis and Detail  18 
 

 Executive Summary  Section 1 
 

 Executive Summary  Engagement Overview and Transaction  Engagement Overview  The Special Committee has requested that Lincoln render an opinion (the “Opinion”) as to whether the Per Share Merger Consideration (as defined below) to be received in the Merger (as defined in the Merger Agreement, as defined herein) by the Public Stockholders (as defined in the Merger Agreement) in respect of the shares of common stock, par value $0.0001 per share, of the Company (the “Company Common Stock”) held thereby, other than any Excluded Shares (as defined in the Merger Agreement) and any Dissenting Shares (as defined in the Merger Agreement), is fair, from a financial point of view, to the Public Stockholders.  Transaction  We understand that the Company proposes to enter into an Agreement and Plan of Merger (the “Merger Agreement”) with NH Holdings 2025, Inc., a Delaware corporation ("Parent"), and NH Holdings Acquisition 2025, Inc, a Delaware corporation (“Merger Sub”), pursuant to which, among other things, Merger Sub will be merged with and into the Company (which transaction constitutes the Merger), with the Company surviving the Merger. Capitalized terms used herein and not otherwise defined herein have the meanings ascribed to such terms in the Merger Agreement.  As more fully described in the Merger Agreement, Lincoln understands that, pursuant to the Merger Agreement, as a result of the Merger, each share of Company Common Stock that is issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) (other than any Excluded Shares and any Dissenting Shares) shall automatically be converted into the right to receive an amount in cash equal to $7.33, without interest (the “Per Share Merger Consideration”).  Further, in connection with the Merger and as more fully described in the Merger Agreement, (i) certain stockholders of the Company will roll over their shares of capital stock of the Company pursuant to the Rollover Agreements to be entered into with Ultimate Parent in exchange for certain equity interests of Ultimate Parent; and (ii) certain investors will agree to provide equity financing pursuant to the Equity Commitment Letter and to guarantee the payment of the liabilities and obligations of Parent and Merger Sub under the Merger Agreement pursuant to the Limited Guaranty.  6 
 

 $0.98  $1.98  $0.00  $3.90  $5.17  $0.00  $2.00  $4.00  $6.00  $8.00  $10.00  Executive Summary  Valuation Analysis Summary  Key Valuation Metrics  WACC range of 23.0% to 25.0%  Terminal Growth Rate of 7.50%  Terminal Adjusted EBITDA Margin of 7.50%  13.0x to 15.0x 2025P EBITDA  of $75 million  5.5x to 6.5x 2026P EBITDA  of $179 million  Liquidation Preference of Series A and Series B Preferred Stock exceeds Aggregate Equity Value  Methodology  Discounted Cash Flow  Analysis  Selected Public Companies Analysis  Intrinsic Value  Estimated Value Per Share of Company Common Stock  Per Share Merger Consideration  $7.33  Note: Above figures from financial projections were provided by Management  7 
 

 Executive Summary  Valuation Analysis Summary  Source: Company Management  Present value of estimated tax savings related to $2.6 billion in federal NOLs and $3.7 billion in state NOLs  As of September 30, 2024  Pro forma for $30 million payment to acquire remaining interest in Centrum (the “Centrum Transaction”)  Note associated with the Centrum Transaction  Owed to Centrum P-Unit holders  $100 million projected to be received in November 2024. $10 million projected to be received in June 2025  Present value of projected March 2025 and September 2026 settlement payment to CMS net of statutory capital and surplus  Primarily reflects obligations resulting from Babylon Health's bankruptcy  Includes various non-operating assets, non-operating liabilities and one-time items  Present value of projected after-tax income attributable to PMA noncontrolling interest  DCF Analysis  Selected Public  Companies Analysis  Low  High  Low  High  Indicated Enterprise Value Range (Before NOLs, Rounded)  $1,060  - $1,195  $985  - $1,150  Present Value of NOL Tax Benefits (1)  170  - 185  170  - 185  Concluded Enterprise Value Range  $1,230  - $1,380  $1,155  - $1,335  Cash and Cash Equivalents (2) (3)  80  - 80  80  - 80  Short-Term Investments (2)  9  - 9  9  - 9  NEA Term Loan (2)  (99)  - (99)  (99)  - (99)  Hercules Term Loan (2)  (30)  - (30)  (30)  - (30)  RRD Healthcare, LLC Note (4)  (64)  - (64)  (64)  - (64)  P-Unit Liability (5)  (8)  - (8)  (8)  - (8)  Expected Remaining Net Proceeds from Molina (6)  110  - 110  110  - 110  CMS Settlement Payment (7)  (215)  - (215)  (215)  - (215)  DCE Deficit Adjustment (8)  (47)  - (47)  (47)  - (47)  Other Items (9)  (14)  - (14)  (14)  - (14)  Estimated Value of PMA Noncontrolling Interest (10)  (102)  - (116)  (102)  - (116)  Equity Value Available to Holders of Preferred Stock and Company Common Stock  $849  - $986  $774  - $941  Implied Concluded Enterprise Value Multiples (Including NOL Tax Benefits)  2025P EBITDA  $75  16.3x  - 18.3x  15.3x  - 17.7x  2026P EBITDA  179  6.9x  - 7.7x  6.4x  - 7.5x  2024E Revenue  940  1.31x  - 1.47x  1.23x  - 1.42x  Valuation Analysis Summary  ($ in millions)  8 
 

 Executive Summary  Valuation Analysis Summary – Company Common Stock  As of September 30, 2024  Provided by Management. See Appendix A for detail  The intrinsic value calculation below allocates the equity value available to holders of preferred stock and Company Common Stock, first to the Series A Preferred Stock and Series B Preferred Stock, on a pari passu basis, and second to the Company Common Stock, after the liquidation preference of the Series A Preferred Stock and Series B Preferred Stock is satisfied. This calculation results in zero value to Company Common Stock.  Further, Lincoln allocated equity value using an option pricing methodology which ascribes option value to the Company Common Stock despite its intrinsic value of zero. This methodology is more fully explained on page 12.  Valuation Analysis Summary  ($ in millions, except per share values)  DCF Analysis  Selected Public  Companies Analysis  Low  High  Low  High   Preference (1)  Series A Preferred Stock $859  ($694)  -  ($805)  ($633)  -  ($768)  Series B Preferred Stock 193  (156)  -  (181)  (142)  -  (172)  Total Preferred Stock 1,052  (849)  -  (986)  (774)  -  (941)  Company Common Stock  $0  -  $0  $0  -  $0  Allocation of Equity Value - Option Pricing Model  Equity Value Available to Holders of Preferred Stock and Company Common Stock  $849  -  $986  $774  -  $941  Value of Company Common Stock  $29  -  $75  $14  -  $56  Fully Diluted Shares Outstanding (2)  14,434,241  -  14,434,241  14,434,241  -  14,434,241  Company Common Stock Per Share Value  $1.98  -  $5.17  $0.98  -  $3.90  Intrinsic Value Calculation  Equity Value Available to Holders of Preferred Stock and Company Common Stock $849 - $986 $774 - $941  Liquidation  9 
 

 Valuation Analysis  Section 2 
 

 Lincoln performed a valuation of (i) the Company on an enterprise value basis and (ii) the Company Common Stock on a per share basis. Lincoln estimated ranges of enterprise values for the Company using each of the following valuation approaches described below assuming the Company would continue to operate as a public company:  Methodology Explanation  Key Updates since August 1, 2024  Discounted Cash Flow Analysis (“DCF”)  (Income Approach)  Present value of projected unlevered free cash flows discounted at a rate commensurate with risk  Key inputs include the budget and financial projections for the Company for the years ending December 31, 2024 through December 31, 2027, provided to us by management of the Company (the “Management Projections”), discount rate, and terminal value assumptions  Captures value associated with long-term cash flow generating ability of the Company  Pro forma for taxes assuming no utilization of historical and future net operating losses (“NOLs”) and therefore excludes value of NOL tax savings, which are separately valued  Utilized updated Management Projections which included revised view of stock-based compensation expense  Market Approach  Selected Public Companies Analysis  ‒ “Public market valuation”  ‒ Value based on market trading multiples of selected public companies using comparisons of various attributes including: relative size, historical and projected growth and profitability, capital intensity, geographic presence, customer mix, payor mix, and other financial performance metrics.  Lincoln did not consider a M&A Transactions Analysis due to the following:  ‒ Lack of relevant recent transactions;  ‒ Historical transactions generally involved strategic acquirers resulting in implied valuation multiples inclusive of synergies  ‒ Valuation multiple for M&A transactions reflects premium for control;  ‒ Generally computed based on historical financial performance (i.e., LTM EBITDA), which is not meaningful for the Company;  Higher 2026P EBITDA given the revision of stock-based compensation expense to the Management Projections  Median 2026P EBITDA multiple of the selected public companies declined from 8.1x to 6.9x resulting in a 0.5x lower selected range on 2026P EBITDA  Selected 2025P EBITDA multiples (previously did not select)  Valuation Analysis  Methodology  11 
 

 Valuation Analysis  Methodology (continued)  Lincoln then estimated ranges of aggregate equity value (“Aggregate Equity Value”) available to the holders of Company Common Stock and the Company’s Series A Preferred Stock and Series B Preferred Stock (the “Preferred Stock”) by adjusting the estimated enterprise value ranges for cash and cash equivalents, non-operating assets, debt and debt-like items, non-operating liabilities and the estimated value of noncontrolling interests.  Given that the aggregate liquidation preference of the Preferred Stock exceeds Lincoln’s estimated ranges of Aggregate Equity Value, Lincoln estimated the value of the Company Common Stock using an option pricing model (“OPM”). This valuation methodology is based on the principles of option pricing theory, whereby the Series A Preferred Stock, Series B Preferred Stock and Company Common Stock are each modeled as call options with a unique claim on the estimated ranges of Aggregate Equity Value. The rights and economic characteristics of each security define these claims. The resulting option claims, in combination, depict the sharing of proceeds between different securities upon a liquidity event. The result is an allocation of the aggregate equity value to each class of security. The effect in this case is an allocation of positive value to the Company Common Stock which represents “option value” despite the Company Common Stock having zero intrinsic value.  The key inputs of OPM include: (i) initial value of an underlying asset; (ii) exercise price; (iii) volatility; (iv) time to expiration; and (v) risk free rate. Lincoln utilized a term of approximately 0.24 years based on March 15, 2025, the current due date of the CMS settlement obligation, which could trigger a recapitalization or liquidity event. Lincoln selected a levered equity volatility of 55% which was based on its review of unlevered volatiles of the selected public companies which were re-levered based on the Company’s current capital structure.  Lincoln divided the resulting Company Common Stock value ranges by fully diluted shares outstanding to derive per share value ranges of the Company Common Stock.  Additionally, Lincoln calculated the intrinsic value of the Company Common Stock to be $0.  12 
 

 Valuation Analysis  DCF Analysis - Summary  Note: 2025P to 2027P pro forma share-based compensation expense provided by Management Source: Management Projections  Normalizes Adjusted EBITDA and Adjusted EBITDA margin based on input from  Management  Q4 2024 Adjusted EBITDA includes normalized stock-based compensation expense estimate  of approximately $3 million  Includes financial guarantees and annual bonus payments  (4) The tax benefits associated with depreciation and amortization (“D&A”) expense were valued separately based on annual tax-deductible D&A expense of $31.5 million from 2024 to 2034,  $30.2 million in 2035, $21.4 million in 2036, and $14.5 million in 2037 and 2038 resulting in the  full D&A of the Company’s existing tax basis of fixed assets, goodwill and intangible assets. No future incremental D&A expense is assumed to be generated as the Management Projections assume approximately $0 of projected capital expenditures and intangible asset capitalization.   Management Projections   FY Ending December 31,  2023A  2024E  2025P  2026P  2027P  Normalized  Terminal (1)  Total Revenue  $1,161  $940  $1,719  $2,712  $3,659  $3,659  % Growth  54.5%  (19.0%)  82.8%  57.7%  34.9%  Adjusted EBITDA Excl. SBC  ($8)  $27  $87  $193  $332  Share-based Compensation ("SBC") Expense   (84)  (72)  (12)  (14)  (16)  Adjusted EBITDA  ($92)  ($45)  $75  $179  $317  $274  % Margin  (7.9%)  (4.8%)  4.4%  6.6%  8.7%  7.5%  % Growth  NMF  NMF  NMF  137.6%  76.7%  10/24 - 12/24  Adjusted EBITDA (2)  $7  $75  $179  $317  $274  Pro Forma Taxes @ 23.5%  (2)  (18)  (42)  (74)  (64)  NOPAT (Before D&A Tax Benefits)  $5  $58  $137  $242  $210  Capital Expenditures  ($1)  $0  $0  $0  $0  Other Operating Cash Flows (3)  9  (0)  (1)  (1)  (1)  (Increase) Decrease in Net Working Capital  0  0  0  0  0  Unlevered Free Cash Flow (Before D&A Tax Benefits)  $13  $57  $136  $241  $209  % Growth  Enterprise Value  Low  NA  137.0%  High  77.2%  Weighted Average Cost of Capital (WACC)  25.00%  -  23.00%  Terminal Growth Rate (TGR)  7.50%  -  7.50%  Present Value of Discrete Cash Flows  $297  -  $306  Present Value of Terminal Value  728  -  856  Present Value of D&A Tax Benefits (4)  33  -  35  Indicated Enterprise Value (Rounded)  $1,060  -  $1,195  Implied Enterprise Value Multiples  2025P EBITDA  $75  14.1x  -  15.8x  2026P EBITDA  179  5.9x  -  6.7x  2024E Revenue  940  1.13x  -  1.27x  Discounted Cash Flow Analysis Summary  ($ in millions)  13 
 

 Valuation Analysis  Selected Public Companies Analysis – Summary  Lincoln considered public companies that operate as managed care organizations (“MCOs”) and value-based care providers (“VBCs”).  Lincoln’s selected multiples for the Company were based on a comparative analysis that considered, among other things, certain quantitative and qualitative factors including the following: relative size, historical and projected growth and profitability, capital intensity, geographic presence, customer mix, payor mix, and other financial performance metrics.  Considering the factors above, Lincoln selected a multiple range of 13.0x to 15.0x 2025P EBITDA and 5.5x to 6.5x 2026P EBITDA.  None of the selected public companies is identical to the Company.  Lincoln does not have access to non-public information regarding those companies.  Source: S&P Capital IQ, company filings, Management Projections  Selected Public Companies   Median Selected Multiples Financial Enterprise Value   Enterprise Value Multiple  Low  - High  MCO  VBC  Consolidated  Low  - High  Statistic  Low  - High  2025P EBITDA  5.8x  - 52.1x  6.7x  21.8x  7.1x  13.0x  - 15.0x  $75  $980  - $1,131  2026P EBITDA  3.5x  - 36.1x  6.3x  10.7x  6.9x  5.5x  - 6.5x  $179  $985  - $1,164  Selected Public Companies Analysis Summary  ($ in millions)  Indicated Enterprise Value Range (Rounded) $985 - $1,150  Implied Enterprise Value Multiples  2025P EBITDA  5.8x  - 52.1x  6.7x  21.8x  7.1x  $75  13.1x  - 15.3x  2026P EBITDA  3.5x  - 36.1x  6.3x  10.7x  6.9x  179  5.5x  - 6.4x  2024E Revenue  0.09x  - 1.38x  0.40x  0.74x  0.44x  940  1.05x  - 1.22x  14 
 

 Valuation Analysis  Selected Public Companies – Financial Metrics  Source: S&P Capital IQ, company filings, Management Projections  EBITDA growth metrics based on EBITDA excluding share-based compensation expense  EBITDA including share-based compensation expense  2024E to 2026P based on Management Projections  Company Name  2023A Financial Statistics  Revenue Growth  EBITDA Growth (1)  Revenue EBITDA (2)  2023A  2024E 2025P  2026P  2023A  2024E 2025P  2026P  MCOs  Alignment Healthcare, Inc.  $1,824  ($102)  27.2%  46.8%  28.7%  22.8%  (32.2%)  96.5%  NMF  85.3%  Centene Corporation  153,999  5,845  6.5%  4.8%  3.9%  2.5%  8.2%  (27.6%)  6.0%  6.6%  Clover Health Investments, Corp.  2,034  (186)  (41.5%)  (32.1%)  15.1%  18.1%  84.6%  NMF  (30.7%)  92.0%  Elevance Health, Inc.  170,209  12,118  9.3%  2.9%  7.2%  7.1%  10.8%  (0.7%)  3.9%  11.4%  Humana Inc.  106,374  5,712  14.5%  9.9%  1.6%  0.7%  4.7%  (30.8%)  4.2%  (8.3%)  Molina Healthcare, Inc.  33,003  1,751  6.1%  22.4%  7.4%  8.6%  9.0%  17.3%  9.8%  11.5%  Oscar Health, Inc.  5,863  (205)  47.9%  57.9%  26.3%  2.4%  90.2%  NMF  86.5%  38.2%  The Cigna Group  195,322  11,980  8.1%  24.9%  3.3%  5.3%  3.7%  10.2%  6.3%  6.7%  UnitedHealth Group Incorporated  371,622  36,330  14.6%  8.0%  9.3%  7.7%  14.1%  5.4%  10.5%  10.7%  Mean - MCOs  $115,583  $8,138  10.3%  16.2%  11.4%  8.3%  21.5%  10.1%  12.1%  28.2%  Median - MCOs  106,374  5,712  9.3%  9.9%  7.4%  7.1%  9.0%  5.4%  6.2%  11.4%  VBCs  agilon health, inc.  $4,316  ($164)  80.7%  40.3%  9.8%  16.0%  (108.9%)  (55.3%)  44.5%  81.5%  Astrana Health, Inc.  1,387  125  21.2%  43.3%  34.3%  24.2%  4.7%  16.3%  23.7%  24.6%  InnovAge Holding Corp.  688  (8)  (1.5%)  12.1%  10.1%  12.1%  NMF  107.0%  57.4%  83.1%  P3 Health Partners Inc.  1,266  (91)  20.7%  19.1%  0.8%  29.6%  33.2%  (49.1%)  59.4%  39.9%  Privia Health Group, Inc.  1,658  35  22.2%  2.3%  11.5%  12.7%  18.7%  23.5%  19.4%  19.9%  Mean - VBCs  $1,863  ($21)  28.7%  23.4%  13.3%  18.9%  (13.1%)  8.5%  40.9%  49.8%  Median - VBCs  1,387  (8)  21.2%  19.1%  10.1%  16.0%  11.7%  16.3%  44.5%  39.9%  Mean - Consolidated  $74,969  $5,224  16.9%  18.8%  12.1%  12.1%  10.8%  9.4%  23.2%  35.9%  Median - Consolidated  5,090  80  14.6%  15.6%  9.6%  10.3%  9.0%  7.8%  10.5%  22.3%  NeueHealth, Inc. (2)  $1,161  ($92)  54.5%  (19.0%)  82.8%  57.7%  88.7%  NMF  227.1%  120.5%  Selected Public Companies Analysis - Financial Metrics  Data Updated Through: December 17, 2024  ($ in millions)  15 
 

 Valuation Analysis  Selected Public Companies – Financial Metrics (continued)  Source: S&P Capital IQ, company filings, Management Projections  EBITDA including share-based compensation expense  2024E to 2026P based on Management Projections   EBITDA Margin (1)   Company Name  2023A  2024E  2025P  2026P  MCOs  Alignment Healthcare, Inc.  (5.6%)  (2.9%)  (1.6%)  (0.9%)  Centene Corporation  3.8%  2.6%  2.7%  2.8%  Clover Health Investments, Corp.  (9.1%)  (2.7%)  (4.4%)  (2.8%)  Elevance Health, Inc.  7.1%  6.9%  6.7%  6.9%  Humana Inc.  5.4%  3.4%  3.5%  3.2%  Molina Healthcare, Inc.  5.3%  5.1%  5.2%  5.3%  Oscar Health, Inc.  (3.5%)  0.9%  1.9%  3.1%  The Cigna Group  6.1%  5.4%  5.6%  5.6%  UnitedHealth Group Incorporated  9.8%  9.5%  9.7%  9.9%  Mean - MCOs  2.1%  3.1%  3.2%  3.7%  Median - MCOs  5.3%  3.4%  3.5%  3.2%  VBCs  agilon health, inc.  (3.8%)  (3.6%)  (2.5%)  (1.4%)  Astrana Health, Inc.  9.0%  7.2%  6.7%  6.8%  InnovAge Holding Corp.  (1.2%)  1.9%  3.1%  5.6%  P3 Health Partners Inc.  (7.2%)  (8.9%)  (3.9%)  (2.0%)  Privia Health Group, Inc.  2.1%  1.9%  2.4%  3.0%  Mean - VBCs  (0.2%)  (0.3%)  1.2%  2.4%  Median - VBCs  (1.2%)  1.9%  2.4%  3.0%  Mean - Consolidated  1.3%  1.9%  2.5%  3.2%  Median - Consolidated  3.0%  2.3%  2.9%  3.1%  NeueHealth, Inc. (2)  (7.9%)  (4.8%)  4.4%  6.6%  Selected Public Companies Analysis - Financial Metrics  Data Updated Through: December 17, 2024  ($ in millions)  16 
 

 Valuation Analysis  Selected Public Companies – Valuation Multiples  Source: S&P Capital IQ, company filings  Enterprise Value = Market Capitalization + Management Equity + Debt + Preferred Stock + Non-Controlling Interest – Cash & Equivalents – Net Non-Operating Assets  (1) EBITDA including share-based compensation expense  EV as a Multiple of (1)  Stock Price as  % of 52  Market  Enterprise  2024  2025  2026  2024  Company Name  of 12/17/24  Week High  Capitalization  Value  EBITDA  EBITDA  EBITDA  Revenue  MCOs  Alignment Healthcare, Inc.  $10.83  76.0%  $2,312  $2,260  NMF  NMF  NMF  0.84x  Centene Corporation  57.81  71.0%  29,618  30,151  7.1x  6.7x  6.3x  0.19x  Clover Health Investments, Corp.  3.21  68.2%  1,875  1,570  NMF  NMF  NMF  1.14x  Elevance Health, Inc.  366.30  64.6%  85,334  83,701  7.0x  6.7x  6.0x  0.48x  Humana Inc.  233.89  49.2%  28,339  29,998  7.6x  7.3x  7.9x  0.26x  Molina Healthcare, Inc.  291.78  68.8%  16,966  14,467  7.0x  6.4x  5.8x  0.36x  Oscar Health, Inc.  13.50  56.7%  3,840  1,299  15.6x  5.8x  3.5x  0.14x  The Cigna Group  265.59  71.6%  74,855  97,314  7.4x  6.9x  6.5x  0.40x  UnitedHealth Group Incorporated  485.52  77.0%  452,234  492,841  12.9x  11.6x  10.5x  1.23x  Mean - MCOs  67.0%  $77,264  $83,733  9.2x  7.4x  6.6x  0.56x  Median - MCOs  68.8%  28,339  29,998  7.4x  6.7x  6.3x  0.40x  VBCs  agilon health, inc.  $2.00  14.9%  $844  $535  NMF  NMF  NMF  0.09x  Astrana Health, Inc.  35.52  56.2%  1,745  1,627  11.4x  9.2x  7.3x  0.82x  InnovAge Holding Corp.  4.08  61.0%  579  597  39.3x  21.8x  10.7x  0.74x  P3 Health Partners Inc.  0.19  10.9%  71  153  NMF  NMF  NMF  0.10x  Privia Health Group, Inc.  20.79  85.6%  2,712  2,337  71.5x  52.1x  36.1x  1.38x  Mean - VBCs  45.7%  $1,190  $1,050  40.7x  27.7x  18.0x  0.63x  Median - VBCs  56.2%  844  597  39.3x  21.8x  10.7x  0.74x  Mean - Consolidated  59.4%  $50,095  $54,204  18.7x  13.5x  10.0x  0.58x  Median - Consolidated  66.4%  3,276  2,299  9.5x  7.1x  6.9x  0.44x  Selected Public Companies Analysis - Valuation Multiples  Data Updated Through: December 17, 2024  ($ in millions, except per share amounts)  17 
 

 Supplemental Analysis and Detail  Appendix A 
 

 Supplemental Analysis and Detail  Premiums Paid Analysis  Source: S&P Capital IQ  Note: Excludes transactions involving special purpose acquisition corporations  VWAP = Volume Weighted Average Price. Calculated as the sum product of Daily VWAP and Daily Volume of the number of days considered divided by the cumulative Daily Volume of the days considered using Daily VWAP and Daily Volume as reported by S&P Capital IQ  Closing price of most recent trading day prior to the announcement date  Closing price of most recent trading day seven calendar days prior to the announcement date  Calculated based on 10 most recent trading days prior to the announcement date  Calculated based on 30 most recent trading days prior to the announcement date  Excludes Pharmaceuticals, Biotechnology, and Life Sciences  Calculated based on 10 most recent trading days prior to and including reference date  Calculated based on 30 most recent trading days prior to and including reference date   Offer Price Premium to   1-Day Price (1)  7-Day Price (2)  10-Day VWAP (3)  30-Day VWAP (4)  All Deals (n = 246)  25th Percentile  15%  16%  17%  19%  Median  30%  31%  32%  35%  75th Percentile  52%  58%  55%  57%  Healthcare Deals (n = 21) (5)  25th Percentile  19%  21%  24%  26%  Median  29%  31%  30%  30%  75th Percentile  44%  42%  43%  42%  Affiliate Deals (n = 17)  25th Percentile  13%  11%  13%  14%  Median  41%  34%  36%  32%  75th Percentile  46%  49%  52%  56%  Per Share Merger  Closing Price  Closing Price  10-Day VWAP (6)  30-Day VWAP (7)  Consideration  as of:  Dec 17, 2024  Dec 10, 2024  Dec 17, 2024  Dec 17, 2024  NeueHealth, Inc.  $7.33  $4.05  $5.24  $4.93  $4.97  Offer Price % Premium  81%  40%  49%  47%  19 
 

 Supplemental Analysis and Detail  Premiums Paid Analysis – Aggregate and Industry  Source: S&P Capital IQ  Note: Excludes transactions involving special purpose acquisition corporations  To identify the relevant transactions in the Premiums Paid Analysis, Lincoln screened S&P Capital IQ using the following criteria:  Total Transaction Value ($USDmm, Historical rate): Is between 500 and 2,500  Target Market Cap 1-Day Prior ($USDmm, Historical rate): is greater than 1  M&A Closed Date: [12/17/2019-12/17/2024]  Geographic Locations (Target/Issuer): United States of America  Percent Sought (%): is greater than 49  Offer per share ($USD, Historical rate): is greater than 0.01 – resulted in All Deals (n = 246)  Industry Classifications (Target/Issuer): Health Care (Primary)  Industry Classifications (Target/Issuer): NOT (Pharmaceuticals, Biotechnology and Life Sciences) – for Health Care Deals (n = 21)  20 
 

 Supplemental Analysis and Detail  Premiums Paid Analysis – Affiliate Deals  Source: S&P Capital IQ  Note: Excludes transactions involving special purpose acquisition corporations  To identify the relevant transactions in the Premiums Paid Analysis, Lincoln screened S&P Capital IQ using the following criteria:  Total Transaction Value ($USDmm, Historical rate): Is between 500 and 2,500  Target Market Cap 1-Day Prior ($USDmm, Historical rate): is greater than 1  M&A Closed Date: [12/17/2019-12/17/2024]  Geographic Locations (Target/Issuer): United States of America  Merger / Acquisition Features: Majority Shareholder Purchasing Remaining Shares OR Minority Shareholder Purchasing Remaining Shares – resulted in Affiliate Deals (n = 17)  21 
 

 NeueHealth, Inc. (NYSE:NEUE) - Historical Trading Summary  In USD  Supplemental Analysis and Detail  Historical NEUE Stock Trading Chart  (1)  Source: S&P Capital IQ  (1) ~ 5.77 million shares of daily trading volume on May 26, 2023  Note: The graph and table above reflects the pricing and volume of NeueHealth’s equity listing under the ticker symbol “NEUE” on the NYSE and is pro forma for the 1-for-80 reverse stock split effective May 22, 2023  $200  $400  $600  $800  $1,000  May-22  Sep-22  Jan-23  Share Price  Volume  Price  0.00  0.40  0.80  1.20  1.60  2.00  $0  Feb-23 Jun-23 Oct-23  $20  $40  $60  $80  $100  Feb-24  Jun-24  Oct-24  Volume (millions)  Volume  Price  $0  Sep-21 Jan-22  NeueHealth, Inc. - Common Stock Overview  Stock Price as of December 17, 2024  $4.05  One-Week Average  11,727  Two -Week Average  10,899  Stock Price as of December 17, 2023  6.19  % of Shares Outstanding  0.1%  % of Shares Outstanding  0.1%  Stock Price as of December 17, 2022  45.39  % of Float  0.3%  % of Float  0.3%  10-Day VWAP  $4.93  One-Month Average  8,494  Six-Month Average  11,359  30-Day VWAP  4.97  % of Shares Outstanding  0.1%  % of Shares Outstanding  0.1%  60-Day VWAP  5.12  % of Float  0.3%  % of Float  0.3%  90-Day VWAP  5.13  52-Week Average Closing Price  $6.32  Equity Analyst Coverage  52-Week High Closing Price  16.35  Firm  Date  Price Target   Ratings  52-Week Low Closing Price  104-Week Average Closing Price  4.05  $14.03  RBC Capital Markets  12/8/2024  $7.00  Sector  Perform  104-Week High Closing Price  83.20  104-Week Low Closing Price  4.05  NeueHealth, Inc. - Historical Daily Trading Volume  22 
 

 Supplemental Analysis and Detail  Equity Capitalization Table  Equity Capitalization Table as of December 17, 2024  Strike Price /  Fully Diluted  ITM  Conversion  Shares O/S  Shares O/S  Price (1)  Common Stock 8,285,786  8,285,786  N/A  RSUs and PSUs (2) 3,045,367  2,940,367  N/A  Warrants 3,208,051  3,208,051  $0.01  Stock Options 426,835  37  $132.93  Fully Diluted Shares 14,966,039  14,434,241  Series A Preferred Stock 3,331,315  0  $260.34  Series B Preferred Stock 2,145,293  0  $90.72  Fully Diluted Shares Including Convertible Preferred Stock 20,442,648  14,434,241  Source: Management O/S = Outstanding ITM = In-the-money  Reflects weighted average strike price for all stock options outstanding  PSUs outstanding are considered out of the money given Management’s expectations that performance hurdles will not be met  23 
 

 Supplemental Analysis and Detail  Debt and Preferred Stock Capitalization Table  Source: Management  Note: Balances as of September 30, 2024  Interest rate consists of 9.65% cash and 2.50% PIK  Maturity date assumed to be 91 days after the Hercules Term Loan maturity date  Pro forma for the Centrum Transaction  Pro forma for $30 million payment related to the Centrum Transaction   Pri  Maturity Date  cing and Ter  Interest Rate  m   Security Feature  Current Balance  Hercules Term Loan (1)  May. '28  12.15%  $30  NEA Debt (2)  Aug. '28  15.00%  99  RRD Healthcare, LLC Note (3)  Oct. '28  6.00%  64  Centurm P-Unit Liability (3)  Oct. '28  6.00%  8  Total Debt  $201  Series A Preferred Stock  Perpetual  5.00%  Convertible  859  Series B Preferred Stock  Perpetual  5.00%  Convertible  193  Total Debt and Preferred Stock  $1,254  Cash and Cash Equivalents (4)  (80)  Short-Term Investments  (9)  Net Debt and Preferred Stock  $1,166  Debt and Preferred Stock Capitalization Table  ($ in millions)  24 
 

 Supplemental Analysis and Detail  Illustrative Implied Transaction Enterprise Value  Source: Merger Agreement, Management and Company filings  25  $ in millions, except Per Share Merger Consideration  Implied Transaction Enterprise Value  Comments / Sources  Per Share Merger Consideration  $7.33  Merger Agreement  (×) Fully Diluted Common Shares Outstanding  14,434,241  Company Management  Implied Common Equity Value  $106  Series A Preferred Stock Liquidation Preference  859  As of September 30, 2024  Series B Preferred Stock Liquidation Preference  193  As of September 30, 2024  Implied Aggregate Equity Value  $1,158  Cash and Debt  Cash and Cash Equivalents  (80)  As of September 30, 2024, pro forma for Centrum Transaction  Short-Term Investments  (9)  As of September 30, 2024  NEA Term Loan  99  As of September 30, 2024  Hercules Term Loan  30  As of September 30, 2024  RRD Healthcare, LLC Note  64  Pro forma for Centrum Transaction  P-Unit Liability  8  Pro forma for Centrum Transaction  Transaction Value  $1,270  Non-operating Assets and Liabilities  Expected Remaining Net Proceeds from Molina  (110)  $100 million projected to be received in November 2024. $10 million projected to be received in June 2025  CMS Settlement Payment  215  Present value of projected March 2025 and September 2026 settlement payment to CMS net of statutory capital and surplus  DCE Deficit Adjustment  47  Primarily reflects obligations resulting from Babylon Health's bankruptcy  Other Items  14  Includes various other non-operating assets, non-operating liabilities and one-time items  Estimated Value of PMA Noncontrolling Interest  109  Present value of projected after-tax income attributable to PMA noncontrolling interest  Implied Transaction Enterprise Value  $1,545 
 

Exhibit (d)(2)

LIMITED GUARANTY
 
THIS LIMITED GUARANTY, dated as of December 23, 2024 (this “Limited Guaranty”), sets forth the terms and conditions of the guarantee of each of the undersigned entities set forth on the signature pages hereto under the heading “Guarantors” (collectively, the “Guarantors” and each of them a “Guarantor”), in favor of NeueHealth, Inc., a Delaware corporation (the “Company”), in connection with the entry into the Agreement and Plan of Merger dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and among the Company, NH Holdings 2025, Inc., a Delaware corporation (“Parent”), and Holdings Acquisition 2025, Inc, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). Capitalized terms used, but not otherwise defined, herein shall have the meanings ascribed to them in the Merger Agreement.
 
1.          Limited Guaranty.
 
(a)        Upon the terms and subject to the conditions set forth in this Limited Guaranty, each Guarantor, severally (and not jointly), and on a pro rata basis in accordance with the percentages indicated on Exhibit A (each such Guarantor’s “Pro Rata Portion”), hereby absolutely, irrevocably and unconditionally guarantees to the Company the due, punctual and complete payment of all of the liabilities and obligations of the Parent Parties under the Merger Agreement, including the payment to the Company of any monetary damages to which the Company is entitled pursuant to, and as limited by, Section 8.3(b) of the Merger Agreement (the “Guaranteed Obligations”), in an aggregate amount up to the Parent Damages Limitation.
 
(b)        Notwithstanding anything to the contrary in this Limited Guaranty or in any other document or agreement, the maximum aggregate liability of each Guarantor under or in respect of this Limited Guaranty shall not exceed such Guarantor’s Pro Rata Portion of the Parent Damages Limitation. The Company (on behalf of itself and the other Company Related Parties, as defined below) hereby agrees that neither the Guarantors nor any Guarantor Affiliate (as defined below) shall have any obligation or liability to any Person relating to, arising out of or in connection with, this Limited Guaranty, the Merger Agreement and/or the Equity Commitment Letter, other than a Retained Claim (as defined below). Each Guarantor’s obligations to pay its Pro Rata Portion of the Guaranteed Obligations shall be automatically reduced by the full amount paid to the Company by or on behalf of Parent with respect to the Guaranteed Obligations and in no event shall the same amounts that are due and payable by Parent under and pursuant to Section 8.3(b) of the Merger Agreement be payable, and in no event shall Parent or the Guarantors pay such amounts, on more than one occasion resulting in duplication of recovery.
 
(c)         All payments hereunder shall be made in lawful money of the United States, by wire transfer of immediately available funds.
 
2.           Conditions to Obligations. The obligation of the Guarantors to fund the Guaranteed Obligations is subject to all or a portion of the Guaranteed Obligations becoming due and payable by Parent pursuant to the Merger Agreement. For the avoidance of doubt, the obligations of Parent under the Merger Agreement shall be determined in accordance with the terms thereof, and nothing in this Limited Guaranty shall amend, modify, expand or waive any of the terms of the Merger Agreement, any defenses that Parent may have to any assertion of liability or obligation against Parent under the Merger Agreement or any rights or remedies that the Company may have under the Merger Agreement.


3.            Terms of Limited Guaranty.
 
(a)       This Limited Guaranty is one of payment, not collection, and a separate Action or Actions in a Chosen Court (as defined below) by the Company may be brought and prosecuted against the Guarantors to enforce this Limited Guaranty, irrespective of whether any Action or Actions is brought against Parent, Merger Sub or any other Person or whether Parent, Merger Sub or any other Person is joined in any such Action or Actions.
 
(b)        Without amending or limiting paragraph 3(e) or paragraph 4, the liability of the Guarantors under this Limited Guaranty shall, to the fullest extent permitted under applicable Law, be absolute, irrevocable and unconditional, irrespective of:
 
(i)         the value, genuineness, validity, illegality or enforceability of the Merger Agreement or the Equity Commitment Letter or any other agreement or instrument referred to herein or therein (other than in the case of (A) defenses to the payment of the Guaranteed Obligations that are available to Parent and/or Merger Sub under the Merger agreement or (B) breach by the Company of this Limited Guaranty);
 
(ii)        any change in the corporate (or limited liability company or partnership) existence, structure or ownership of Parent, Merger Sub or any Guarantor or any release or discharge of any obligation of Parent, Merger Sub or any Guarantor under the Merger Agreement resulting therefrom;
 
(iii)       any insolvency, bankruptcy, reorganization, moratorium, dissolution, liquidation or other similar proceeding affecting Parent, Merger Sub or any Guarantor or any of their respective assets;
 
(iv)       any waiver, amendment or modification of the Merger Agreement in accordance with its terms, or change in the time, manner, place or terms of payment or performance, or any change or extension of the time of payment or performance of, renewal or alteration of, any Guaranteed Obligation or any agreement entered into by any party to the Merger Agreement in connection therewith;
 
(v)        the existence of any claim, set off or other right that a Guarantor may have at any time against Parent, Merger Sub or the Company, whether in connection with any Guaranteed Obligation or otherwise (subject to paragraph 3(e));
 
(vi)      the failure or delay on the part of the Company to assert any claim or demand or to enforce any right or remedy against Parent, Merger Sub or any Guarantor or the adequacy of any means the Company may have of obtaining payment related to the Guaranteed Obligations;
 

(vii)      the addition, substitution or release of any Person now or hereafter liable with respect to the Guaranteed Obligations or otherwise interested in the transactions contemplated by the Merger Agreement;
 
(viii)    any change in Laws of any jurisdiction, or any present or future Order, amending, varying, reducing or otherwise affecting the validity or enforcement of any Guaranteed Obligations or the obligations of any Guarantor in respect of any Guaranteed Obligations; or
 
(ix)       any other state of facts, act or omission that may or might in any manner or to any extent vary the risk of any Guarantor or otherwise operate as a release or discharge of any Guarantor as a matter of law or equity (other than as a result of the indefeasible payment in full of the Guaranteed Obligations, the termination of any Guarantor’s obligations hereunder pursuant to paragraph 4 or the assertion of defenses as permitted by paragraph 3(e)).
 
(c)       Each Guarantor hereby waives any and all notice of the creation, renewal, extension or accrual of any of the Guaranteed Obligations and notice of or proof of reliance by the Company upon this Limited Guaranty or acceptance of this Limited Guaranty. The Guaranteed Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred in reliance upon this Limited Guaranty, and all dealings between Parent or the Guarantors, on the one hand, and the Company, on the other hand, shall likewise be conclusively presumed to have been had or consummated in reliance upon this Limited Guaranty. When pursuing its rights and remedies hereunder against any Guarantor, the Company shall be under no obligation to pursue such rights and remedies it may have against Parent, Merger Sub or any other Person for the Guaranteed Obligations or any right of offset with respect thereto, and any failure by the Company to pursue such other rights or remedies or to collect any payments from Parent, Merger Sub or any such other Person or to realize upon or to exercise any such right of offset, and any release by the Company of Parent or any such other Person or any right of offset, shall not relieve any Guarantor of any liability or obligation hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of the Company.
 
(d)       The Company shall not be obligated to file any claim relating to any Guaranteed Obligation in the event that Parent or Merger Sub becomes subject to a bankruptcy, reorganization, insolvency, moratorium, dissolution, liquidation or similar proceeding, and the failure of the Company to so file shall not affect any Guarantor’s obligations hereunder. Notwithstanding any other provision of this Limited Guaranty or in any other document or agreement, in the event that any payment to the Company in respect of any Guaranteed Obligation is rescinded or must otherwise be (and is) returned for any reason whatsoever, each Guarantor shall remain liable hereunder with respect to its Pro Rata Portion of the Guaranteed Obligations as if such payment had not been made.
 

(e)        Notwithstanding any other provision of this Limited Guaranty or in any other document or agreement, the Company hereby agrees (on its own behalf and on behalf of the other Company Related Parties) that each Guarantor may assert as a defense to, or release or discharge of, any payment or performance by such Guarantor under or in respect of this Limited Guaranty any defense, discharge or release that Parent or Merger Sub could assert against the Company under the terms of the Merger Agreement, including, without limitation, any breach by the Company of any representation, warranty or covenant contained therein that would relieve Parent or Merger Sub of its obligations under the Merger Agreement, but in each case excluding any defenses, discharges or releases that may be available or apply by virtue of any bankruptcy, insolvency, reorganization, liquidation, stay, moratorium or other similar Laws.
 
(f)        Without amending or limiting paragraph 3(e) or paragraph 4, each Guarantor irrevocably waives (x) any promptness, diligence, acceptance hereof, presentment, demand, protest and any notice of any kind not required to be provided by the Company to Parent or Merger Sub under or in connection with the Merger Agreement and (y) any and all other rights and defenses arising by reason of any Law that would otherwise require any election of remedies by the Company, other than defenses that are available to (i) Parent or Merger Sub under the Merger Agreement or any of the agreements, certificates and other documents executed by the Company in connection with the transactions contemplated by the Merger Agreement (such other agreements, certificates and documents, the “Ancillary Agreements”) (excluding any defenses that may be available by virtue of any bankruptcy, insolvency, reorganization, liquidation, stay, moratorium or other similar Laws) and (ii) a Guarantor in respect of a breach by the Company of any of its covenants or agreements in this Limited Guaranty. Each Guarantor acknowledges that it will receive substantial direct and indirect benefits from the transactions contemplated by the Merger Agreement and that the waivers set forth in this Limited Guaranty are knowingly made in contemplation of such benefits.
 
4.          Termination of Guarantor Obligations. All obligations of the Guarantors under and in respect of this Limited Guaranty shall automatically and immediately terminate ab initio, and be null and void, and expire, and the Company shall have no rights, obligations or liabilities hereunder and the Guarantors and the Guarantor Affiliates shall have no rights, obligations or liabilities hereunder in connection with or related to this Limited Guaranty, from and after the earliest to occur of the following:
 
(i)         the Closing (including delivery of the aggregate Per Share Merger Consideration payable to the Eligible Holders to the Paying Agent) and the funding in full of the Commitment (as defined in the Equity Commitment Letter) under the Equity Commitment Letter, as such Commitment may be reduced pursuant to the terms thereof;
 
(ii)         the indefeasible payment to the Company by or on behalf of the Guarantors or Parent of the Guaranteed Obligations hereunder in an amount equal to the Parent Damages Limitation or such lesser amount as may be forth in a final, non‑appealable order of a Chosen Court or by written agreement of the Guarantors and the Company;
 

(iii)       the 90th day after the valid termination of the Merger Agreement in accordance with its terms (other than pursuant to Section 8.1(b) of the Merger Agreement, which is addressed by clause (iv) below) unless prior to the 90th day after such termination, the Company shall have commenced an Action against Parent or the Guarantors alleging that all or a portion of the Guaranteed Obligations are payable by Parent under Section 8.3(b) of the Merger Agreement (a “Qualifying Suit”);
 
(iv)       the termination of the Merger Agreement in accordance with its terms pursuant to Section 8.1(b) of the Merger Agreement; and
 
(v)        the Company or any of its controlled Affiliates institutes any Action or makes any written claim against any Guarantor or any Guarantor Affiliate in any such Action (A) asserting that any of the provisions of this Limited Guaranty limiting the liability of any Guarantor or any Guarantor Affiliate are illegal, invalid or unenforceable in whole or in part or any Guarantor is liable in excess of or to a greater extent than such Guarantor’s Pro Rata Portion of the Guaranteed Obligations or the Parent Damages Limitation in connection with this Limited Guaranty, (B) arising under, or in connection with, this Limited Guaranty, the Merger Agreement, the Equity Commitment Letter or the transactions contemplated hereby or thereby, other than a Retained Claim, or (C) in respect of a Retained Claim in any court other than a Chosen Court.
 
In the event that the Merger Agreement has been terminated in accordance with its terms and a Qualifying Suit is filed prior to the 90th day after such termination, this Limited Guaranty shall remain in effect and (A) the Guarantors shall not have any further liability or obligation under this Limited Guaranty from and after the earliest of (i) a final, non‑appealable resolution by a Chosen Court of such Qualifying Suit determining that either (x) Parent and Merger Sub do not have any liability to the Company under the Merger Agreement in respect of the Guaranteed Obligations or (y) the Guarantors do not owe any amount pursuant to paragraph 1 of this Limited Guaranty, (ii) a written agreement between the Guarantors and the Company (with the prior approval of the Special Committee) terminating the obligations and liabilities of the Guarantors with respect to the Guaranteed Obligations, and (iii) the indefeasible payment in full of the Guaranteed Obligations determined by a Chosen Court in a final, non‑appealable judgment to be due and owing (or agreed in writing by the Company to be due and owing) by or on behalf of Parent or the Guarantors, and (B) for the avoidance of doubt, the Guarantors shall remain liable under this Limited Guaranty solely with respect to each Guarantor’s Pro Rata Portion of the Guaranteed Obligations pertaining to such Qualifying Suit on the terms and subject to the conditions and limitations set forth herein (including, for the avoidance of doubt, the Parent Damages Limitation).
 
5.            Exclusive Remedy; No Recourse; Other Agreements.
 
(a)        The Company acknowledges and agrees, on its own behalf and on behalf of the other Company Related Parties, that neither Parent nor Merger Sub has any assets, other than, in each case, its rights under the Merger Agreement and, in the case of Parent, the Equity Commitment Letter, and that no funds are expected to be contributed to Parent or Merger Sub unless the Closing occurs, and that, except for rights of the Company to the extent expressly provided in the Equity Commitment Letter subject to all of the terms, conditions and limitations therein, the Company shall not have any right to cause any assets to be contributed to Parent by the Guarantors, any Guarantor Affiliate or any other Person.
 

(b)        The Company, on its own behalf and on behalf of the other Company Related Parties, further agrees and acknowledges that no Person other than the Guarantors has any obligations hereunder and that, notwithstanding that any Guarantor may be a partnership or limited liability company, recourse or right of recovery against, or contribution from, (i) Parent or Merger Sub, (ii) any former, current or future general or limited partner, stockholder, holder of any equity, partnership or limited liability company interest, officer, member, manager, director, employee, agent, attorney, controlling Person, assignee or Affiliate or other Representative (as defined below) of or any fund under common control with any Guarantor, Parent or Merger Sub, (iii) any lender or prospective lender, lead arranger, arranger, agent or Representative of or to Parent or Merger Sub or (iv) any former, current or future general or limited partner, stockholder, holder of any equity, partnership or limited liability company interest, officer, member, manager, director, employee, agent, attorney, controlling Person, assignee, Subsidiary or Affiliate or other Representative of any of the foregoing (those Persons described in the foregoing clauses (i) through (iv), but excluding the Guarantors, being referred to herein collectively as “Guarantor Affiliates”), through any Guarantor, Parent, Merger Sub or otherwise, whether by or through attempted piercing of the corporate (or limited liability company or partnership) veil or similar Action, by the enforcement of any assessment or by any legal or equitable proceeding, by virtue of any statute, regulation or applicable Law, by or through a claim by or on behalf of any Guarantor, Parent or Merger Sub or against any Guarantor or any Guarantor Affiliate, or otherwise, in each case, under this Limited Guaranty, except for Retained Claims.
 
(c)        Notwithstanding anything to the contrary that may be expressed or implied in this Limited Guaranty or any document or instrument delivered in connection herewith, the Company hereby covenants and agrees that it shall not, and shall cause each of its controlled Affiliates and instruct the other Company Related Parties not to, institute, directly or indirectly, any Action or bring any other claim arising under, or in connection with, this Limited Guaranty, the Merger Agreement, the Equity Commitment Letter, the other Ancillary Agreements or the transactions contemplated hereby or thereby, against any Guarantor or any Guarantor Affiliate except for the following: (i) Actions and claims by the Company against any Guarantor (or its assignees or successors) under and in accordance with, and subject to all of the terms, conditions and limitations in, this Limited Guaranty, (ii) Actions and claims by the Company against Parent or Merger Sub (or their respective assignees or successors) under and in accordance with the Merger Agreement, including, without limitation, the Company’s right to specific performance pursuant to Section 10.1 of the Merger Agreement, (iii) (A) to the extent (but only to the extent) the Company is expressly entitled to cause Parent to enforce the Equity Commitment Letter in accordance with Section 3 of the Equity Commitment Letter subject to all of the terms, conditions and limitations therein, Actions and claims by the Company against Parent seeking to cause Parent to enforce the obligations of the Guarantors to fund the Commitment (as defined in the Equity Commitment Letter) under and in accordance with the Equity Commitment Letter, and (B) Actions and claims by the Company seeking to enforce its third party beneficiary rights under and in accordance with the Equity Commitment Letter, and (iv) Actions and claims by any party to the Confidentiality Agreement against any other party to the Confidentiality Agreement under and in accordance with the Confidentiality Agreement (clauses (i) – (iv), collectively, the “Retained Claims”). Notwithstanding any provision of this Limited Guaranty, no provision of this Limited Guaranty shall waive, limit, restrict or impair any Retained Claim.
 

(d)        Recourse with respect to Retained Claims by the Persons entitled to bring any such Retained Claim shall be the sole and exclusive remedy of the Company and the other Company Related Parties against the Guarantors or any Guarantor Affiliate in respect of any liabilities or obligations arising under, or in connection with, the Merger Agreement, the Equity Commitment Letter, this Limited Guaranty, the other Ancillary Agreements or the transactions contemplated hereby or thereby, and such recourse shall be subject to the limitations described herein or therein, as applicable.
 
6.          Continuing Limited Guaranty. Except to the extent that the obligations and liabilities of the Guarantors are terminated pursuant to paragraph 4 or are released, discharged or otherwise relieved pursuant to paragraph 3(e), this Limited Guaranty is a continuing one and shall remain in full force and effect until the indefeasible payment and satisfaction in full of the Guaranteed Obligations, shall be binding upon each Guarantor, its successors and assigns, and shall inure to the benefit of, and be enforceable by, the Company and its successors and permitted assigns. All obligations to which this Limited Guaranty applies or may apply under the terms hereof shall be conclusively presumed to have been created in reliance hereon.
 
7.           No Third-Party Beneficiaries. Except for the provisions of this Limited Guaranty which reference Guarantor Affiliates (each of which shall be for the benefit of and enforceable by each Guarantor Affiliate), the parties hereby agree that any and all provisions of this Limited Guaranty are solely for the benefit of the parties hereto and their respective successors and permitted assigns, and are not intended to, nor do they confer any benefits on, or create any rights or remedies in favor of, any Person other than the parties hereto and their respective successors and permitted assigns, including the right to rely upon the representations and warranties set forth herein.
 
8.          Relationship of the Parties. Each party hereto acknowledges and agrees that, notwithstanding anything contained herein to the contrary, (a) this Limited Guaranty is not intended to, and does not, create any agency, partnership, fiduciary or joint venture relationship between or among any of the parties hereto and neither this Limited Guaranty nor any other document or agreement entered into by any party hereto relating to the subject matter hereof shall be construed to suggest otherwise, and (b) the obligations of the Guarantors under this Limited Guaranty are solely contractual in nature. Notwithstanding anything to the contrary contained in this Limited Guaranty, the liability of each Guarantor with respect to this Limited Guaranty shall not exceed the lesser of (i) such Guarantor’s Pro Rata Portion of the Guaranteed Obligations due and owing hereunder and (ii) such Guarantor’s Pro Rata Portion of the Parent Damages Limitation. In no event shall Parent or any Guarantor be considered a “Company Related Party” or an “Affiliate”, “member”, “security holder” or “representative” of the Company or another Company Related Party for any purpose of this Limited Guaranty.
 

9.         Amendments, etc. Except for amendments solely to the extent necessary to assign all or any portion of the Guaranteed Obligations as set forth in and to the extent permitted under paragraph 16, this Limited Guaranty may not be amended or otherwise modified (in whole or in part) without the prior written consent of the Company (with the prior authorization of the Special Committee) and each Guarantor, and no waiver of any provision of this Limited Guaranty shall be effective against the party against whom the waiver is to be enforced without the prior written consent of such party. Each provision of this Limited Guaranty may only be waived by written instrument making specific reference to this Limited Guaranty signed by the party against whom enforcement of such provision so waived is sought (in the case of the Company, with the prior authorization of the Special Committee). No waiver by any party of any breach or violation of, or default under, this Limited Guaranty, whether intentional or not, will be deemed to extend to any prior or subsequent breach, violation, or default hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. No delay or omission on the part of any party in exercising any right, power or remedy under this Limited Guaranty will operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.
 
10.       Confidentiality. This Limited Guaranty is being provided solely in connection with the transactions contemplated by the Merger Agreement, and the Company agrees that it will not, nor will it permit any of its controlled Affiliates to, and will instruct the other Company Related Parties not to, disclose to any Person the contents or existence of this Limited Guaranty or the Equity Commitment Letter, or otherwise permit this Limited Guaranty or the Equity Commitment Letter to be disclosed, circulated, quoted or otherwise referred to in any document (other than the Merger Agreement, the Equity Commitment Letter, the Proxy Statement and the Schedule 13E-3), except with the prior written consent of each Guarantor, provided that no such consent shall be required for disclosures by the Company (a) to its Affiliates, directors, employees and attorneys, (b) to the extent required by applicable Law or the rules of any national securities exchange and (c) in connection with any dispute or litigation relating to the Merger Agreement or the transactions contemplated by the Merger Agreement.
 
11.       Notices. All notices and other communications under this Limited Guaranty shall be in writing and shall be deemed given (i) when delivered personally by hand (with written confirmation of receipt, by other than automatic means, whether electronic or otherwise), (ii) when sent by e-mail (with non-automated written confirmation of receipt) or (iii) one (1) Business Day following the day sent by a national overnight courier or an internationally recognized overnight courier (with written confirmation of receipt), in each case at the following addresses (or to such other address as a party may have specified by notice given to the other party pursuant to this provision):
 
If to any Guarantor, to:

c/o New Enterprise Associates
1954 Greenspring Drive, Suite 600
Timonium, MD 21093
Attn:        Stephanie Brecher
Email:      sbrecher@NEA.com

with a copy (which shall not constitute notice) to:

Latham & Watkins LLP
330 N Wabash Avenue, Suite 2800
Chicago, IL 60611
Attn:        Daniel R. Breslin
 

Email:      daniel.breslin@lw.com
Attn:        Max Schleusener
Email:      max.schleusener@lw.com
 
If to the Company to:

NeueHealth, Inc.
9250 NW 36th St., Suite 420
Doral, FL 33178
Attn:      Jeff Craig
Email:    jcraig@neuehealth.com
 
with a copy (which shall not constitute notice) to:

c/o Simpson Thacher & Bartlett LLP
2475 Hanover Street
Palo Alto, CA 94304
Attn:        Atif I. Azher
Email:     aazher@stblaw.com
 
12.        Governing Law. This Limited Guaranty, and all claims or causes of action (whether in contract, tort or otherwise) that may be based upon, arise out of, or related to this Limited Guaranty or the negotiation, execution or performance of this Limited Guaranty (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in connection with this Limited Guaranty), shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws.
 
13.        Jurisdiction; Venue; Service of Process. Each of the parties hereby irrevocably and unconditionally (a) submits, for itself and its property, to the exclusive jurisdiction of the Delaware Court of Chancery (or, only if the Delaware Court of Chancery lacks subject matter jurisdiction, the state or federal courts in the State of Delaware), and any appellate court from any thereof (in such order of priority, the “Chosen Courts”), in any Action arising out of or relating to this Limited Guaranty or the negotiation, execution or performance of this Limited Guaranty (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Limited Guaranty), or for recognition or enforcement of any judgment, and agrees that all claims in respect of any such Action shall be heard and determined in such Delaware Court of Chancery (or, only if the Delaware Court of Chancery lacks subject matter jurisdiction, the state or federal courts in the in the State of Delaware), (b) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any Action arising out of or relating to this Limited Guaranty or the negotiation, execution or performance of this Limited Guaranty (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Limited Guaranty) in the aforementioned courts, (c) waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the maintenance of such Action in any such court and (d) agrees that a final judgment in any such Action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. Each of the parties agrees that service of process, summons, notice or document by registered mail addressed to it at the applicable address set forth in paragraph 11 shall be effective service of process for any Action brought in any such court.
 

14.        Waiver of Jury Trial. THE PARTIES HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS LIMITED GUARANTY OR ANY TRANSACTION CONTEMPLATED HEREBY OR THE ACTIONS OF THE PARTIES IN THE NEGOTIATION, EXECUTION, PERFORMANCE AND ENFORCEMENT OF THIS LIMITED GUARANTY, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR LIMITED GUARANTY AMONG THE PARTIES IRREVOCABLY TO WAIVE TRIAL BY JURY AND THAT ANY ACTION OR PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS LIMITED GUARANTY, THE EQUITY COMMITMENT LETTER OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY SHALL INSTEAD BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.
 
15.        Representations and Warranties. Each Guarantor hereby represents and warrants to the Company that (a) it has all limited partnership, limited liability company, corporate or similar power and authority to execute, deliver and perform this Limited Guaranty; (b) the execution, delivery and performance of this Limited Guaranty by such Guarantor has been duly and validly authorized and approved by all necessary limited partnership, limited liability company, corporate or similar action by it; (c) this Limited Guaranty has been duly and validly executed and delivered by it and constitutes a valid and legally binding obligation of it, enforceable against it in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors’ rights and subject to general principles of equity); (d) the execution, delivery and performance by such Guarantor of this Limited Guaranty do not and will not breach, conflict with or violate the organizational documents of such Guarantor, any Laws applicable to such Guarantor or any Contracts to which it is a party or otherwise bound; (e) it has, and, until all of such Guarantor’s obligations under this Limited Guaranty are terminated in accordance with paragraph 4, will have, the financial capacity to pay and perform all of its obligations under this Limited Guaranty (whether in the form of uncalled capital commitments or other sources of immediately available funds); and (f) it is a limited partnership, limited liability company, corporation or other legal entity, duly organized, validly existing and in good standing under the Laws of the jurisdiction of its formation.
 

16.        Assignment. Neither any Guarantor nor the Company may, directly or indirectly, assign any of its rights, interests or obligations hereunder to any other Person (by operation of law or otherwise) without the prior written consent of the other party hereto. Notwithstanding the foregoing, each Guarantor may assign all or any portion of its Pro Rata Portion of the Guaranteed Obligations to one or more affiliated investment funds of such Guarantor or any of its Affiliates, and its obligation hereunder to fund the Guaranteed Obligations will be reduced on a dollar‑for‑dollar basis by any amounts actually paid to the Company, directly or indirectly, by such Persons in respect of its Pro Rata Portion of the Guaranteed Obligations; provided that (a) no such assignment shall relieve such Guarantor of its obligations hereunder except to the extent actually performed and the Company shall not be required to seek to enforce its rights hereunder against any assignee prior to seeking to enforce its rights hereunder against such Guarantor and (b) such assignment does not result in any additional consent or approval of, or filing, declaration or registration with, any Governmental Authority being required to consummate the transactions contemplated by the Merger Agreement or have the effect of preventing, impairing or delaying the transactions contemplated by the Merger Agreement or the satisfaction of the Guaranteed Obligations. Any attempted assignment in violation of this paragraph 16 shall be null and void and of no force and effect.
 
17.       Complete Agreement. This Limited Guaranty, together with the Merger Agreement, the Equity Commitment Letter, the Confidentiality Agreement and the other documents contemplated hereby and thereby, constitutes the entire agreement of, by or among the parties hereto (and their respective Representatives and Guarantor Affiliates) with respect to the subject matter hereof and supersedes any and all prior discussions, negotiations, proposals, undertakings, understandings, agreements and/or arrangements, whether written or oral, with respect to such subject matter.
 
18.        Counterparts; pdf Format. This Limited Guaranty, and any amendments, modifications or waivers hereto, (a) may be executed in any number of counterparts, each of which will be deemed an original instrument, and all of which together will constitute one and the same agreement, and (b) to the extent signed and delivered by e‑mail delivery of a “.pdf” format data file or by any electronic signature, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No party hereto or to any such agreement or instrument shall raise the use of e‑mail delivery of a “.pdf” format data file or any such electronic signature to deliver a signature to this Limited Guaranty or any amendment hereto or the fact that any signature or agreement or instrument was transmitted or communicated through the use of e‑mail delivery of a “.pdf” format data file or any such electronic signature as a defense to the formation of a contract and each party hereto forever waives any such defense. This Limited Guaranty will become effective when duly executed by each party hereto.
 
19.        Headings; Construction. The headings contained in this Limited Guaranty are for convenience purposes only and will not in any way affect the meaning or be used in construing or interpretation hereof. The parties hereto have participated jointly in the negotiation and drafting of this Limited Guaranty. If any ambiguity or question of intent or interpretation arises, this Limited Guaranty shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Limited Guaranty.
 
20.        Severability. If any term or provision of this Limited Guaranty is invalid, illegal or incapable of being enforced by any Law or public policy, all other terms or provisions of this Limited Guaranty shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party; provided that this Limited Guaranty may not be enforced without giving effect to the limitation of the amount payable hereunder in respect of the Guaranteed Obligations as provided in paragraph 1 (including, for the avoidance of doubt, the Parent Damages Limitation) and to the provisions of paragraph 5. Upon any such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Limited Guaranty so as to effect the original intent of the parties as closely as possible.
 

21.       Equity Commitment Letter. Without limiting, waiving, restricting or impairing any of the Company’s rights under the Merger Agreement, the Company (on behalf of itself and the other Company Related Parties) hereby acknowledges that it has received a fully executed copy of the Equity Commitment Letter, and acknowledges and agrees that, except as expressly and to the extent provided in Section 3 of the Equity Commitment Letter, nothing contained herein or therein shall entitle the Company or any other Company Related Party to (a) enforce specifically the Equity Commitment Letter or (b) otherwise have any rights as a third party beneficiary against any Guarantor or Parent under the Equity Commitment Letter.
 
22.       Certain Definitions. For purposes of this Limited Guaranty, (a) “Company Related Party” means each and any of the following: (i) the Company, its Subsidiaries and their respective Representatives; (ii) former, current or future managers, directors, officers, employees, agents or other Representatives of any of the Persons described in clause (i) of this definition; or (iii) any successor, assignee or heir of any of the Persons described in clause (i) or (ii) of this definition and (b) “Representative” of any Person means such Person’s respective officers, directors, principals, partners, managers, members, attorneys, accountants, agents, employees, consultants, financial advisors or other authorized representatives.
 
* * * * * * *
 

IN WITNESS WHEREOF, the undersigned have executed and delivered this Limited Guaranty as of the date first written above.
 
 
GUARANTORS:
 
     
 
NEA 18 VENTURE GROWTH EQUITY, L.P.
 
 
 
By: NEA PARTNERS 18 VGE, L.P.,
 
Its General Partner
   
 
By: NEA 18 VGE, LLC,
 
Its General Partner
      
 
By:
/s/ Stephanie Brecher
 
 
Name:
Stephanie Brecher
 
Title:
Chief Legal Officer  

 
NEW ENTERPRISE ASSOCIATES 17, L.P.
 
By: NEA PARTNERS 17, L.P.,
 
Its General Partner
   
 
By: NEA 17 GP, LLC,
 
Its General Partner
   
 
By:
/s/ Stephanie Brecher
 
 
Name:
Stephanie Brecher
 
Title:
Chief Legal Officer  


 
NEW ENTERPRISE ASSOCIATES 16, L.P.
 
By: NEA PARTNERS 16, L.P.,
 
Its General Partner
   
 
By: NEA 16 GP, LLC,
 
Its General Partner
   
 
By:
/s/ Stephanie Brecher
 
 
Name:
Stephanie Brecher
 
Title:
Chief Legal Officer  

 
NEW ENTERPRISE ASSOCIATES 15, L.P.
 
BY: NEA PARTNERS 15, L.P., Its General Partner
 
BY: NEA 15 GP, LLC, Its General Partner
   
 
By:
/s/ Stephanie Brecher
 
 
Name:
Stephanie Brecher
 
Title:
Chief Legal Officer  


 
COMPANY:
   
 
NeueHealth, Inc
   
  /s/ Jeff Craig
 
 
Name:
   
 
Title:
   


Exhibit A


Guarantor
Pro Rata Portion

New Enterprise Associates 15, L.P.
25%

New Enterprise Associates 16, L.P.
25%

New Enterprise Associates 17, L.P.
25%

NEA 18 Venture Growth Equity, L.P.
25%

Total
100.00%

 

Exhibit (d)(4)

Commitment Letter

New Enterprise Associates
1954 Greenspring Drive, Suite 600
Timonium, MD 21093


December 23, 2024

NH Holdings 2025, Inc.
c/o New Enterprise Associates
1954 Greenspring Drive, Suite 600
Timonium, MD 21093

Ladies and Gentlemen:

Reference is hereby made to that certain Agreement and Plan of Merger, dated as of the date hereof (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and among NH Holdings 2025, Inc., a Delaware corporation (“Parent”), NeueHealth, Inc., a Delaware corporation (the “Company”), and NH Holdings Acquisition 2025, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). Capitalized terms used but not defined herein have the meanings ascribed to them in the Merger Agreement.

1.          Commitment. Each of the undersigned entities set forth on the signature pages hereto under the heading “Sponsors” (collectively, the “Sponsors” and each of them a “Sponsor”) hereby commits, severally (and not jointly), and on a pro rata basis in accordance with the percentages indicated on Exhibit A (each such Sponsor’s “Pro Rata Portion”), subject to the terms and conditions set forth in this letter agreement (including Section 2), that at the Closing, the Sponsors shall purchase, and/or cause the purchase of, securities of Parent for cash in an aggregate amount equal to $30,000,000 (the “Commitment”), which capital shall be used by Parent solely for the purpose of funding, to the extent necessary to fund, the payment by Parent at the Closing of the Required Amount pursuant to, and in accordance with, the Merger Agreement, on the terms and subject to the conditions of the Merger Agreement; provided, however, that (a) the Sponsors and/or their Affiliates shall not, under any circumstances, be obligated to contribute to, purchase securities of, or otherwise provide funds to, Parent in any amount in excess of the Commitment, (b) the capital provided by the Sponsors and/or their Affiliates to Parent pursuant to this letter agreement may only be used by Parent to satisfy the obligations described in this sentence, and not for any other purpose, and (c) funding of the Commitment will occur contemporaneous with the Closing and the simultaneous issuance to the Sponsors and/or their Affiliates of securities of Parent.  Each Sponsor may effect the purchase of securities of Parent directly or indirectly through one or more Affiliates.  The amount of the Commitment to be funded under this letter agreement will be reduced, dollar for dollar, to the extent that Parent does not require the full Commitment to pay the Required Amount at the Closing by reason of Parent obtaining funds available to pay the Required Amount from other sources.


2.         Conditions.  The Commitment, including the obligation of each Sponsor to fund, or cause the funding of, its Pro Rata Portion of the Commitment, shall be subject to (a) the satisfaction in full, or waiver by Parent (which waiver each Sponsor consents to in writing), of each of the conditions set forth in Section 7.1 and Section 7.2 of the Merger Agreement (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction of such conditions prior to or substantially concurrent with the Closing) and (b) (i) the substantially concurrent completion of the Closing in accordance with the terms of the Merger Agreement or (ii) the Company having irrevocably confirmed to Parent in writing that (A) each of the conditions set forth in Section 7.1 and Section 7.3 of the Merger Agreement have been and continue to be satisfied or waived (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction of such conditions prior to or substantially concurrent with the Closing) and (B) the Company is ready, willing and able to consummate the Closing.

3.         Limited Guaranty; Enforceability.  Concurrently with the execution and delivery of this letter agreement, each Sponsor is executing and delivering to the Company a limited guaranty, dated as of the date hereof (the “Limited Guaranty”).  Notwithstanding anything in this letter agreement or the Limited Guaranty to the contrary, each Sponsor agrees and acknowledges that the Company is a third party beneficiary of this letter agreement and has the right to seek specific performance of each Sponsor’s obligation to contribute capital and fund the Commitment, in each case, if and only to the extent permitted by, and subject to the limitations set forth in, Section 10.1 of the Merger Agreement.  This letter agreement may only be enforced by (a) Parent or (b) the Company pursuant to the Company’s right to seek specific performance of each Sponsor’s obligation to contribute capital and fund the Commitment to the extent permitted by, and subject to the limitations set forth in, Section 10.1 of the Merger Agreement and for no other purpose (including, without limitation, any claim for monetary damages hereunder), and no other third party shall have any right to enforce this letter agreement or to cause Parent to enforce this letter agreement.  Notwithstanding anything that may be expressed or implied in this letter agreement, or any document or instrument delivered contemporaneously herewith, for the avoidance of doubt, in no event shall a Sponsor have any obligation to make any payment or contribution hereunder at any time after the Sponsors have made payment of the Guaranteed Obligations (as defined in the Limited Guaranty) in full under the Limited Guaranty.
 
4.           Enforceability by Creditors.  Parent’s creditors shall have no right to enforce this letter agreement or to cause Parent to enforce this letter agreement.
 
5.          No Modification; Entire Agreement.  This letter agreement may not be amended or otherwise modified without the prior written consent of Parent, each Sponsor and the Company; provided, however, that the Sponsors may amend this letter agreement solely to the extent necessary to reflect any assignment permitted by Section 6 (solely to the extent such assignment is permitted hereby).  Parent hereby acknowledges and agrees that it shall not agree to amend or otherwise modify, or waive any of its rights under, the Merger Agreement without the prior written consent of each Sponsor.  Together with the Merger Agreement, the Confidentiality Agreement and the Limited Guaranty, this letter agreement constitutes the sole agreement, and supersedes all prior agreements, understandings and statements, written or oral, between each Sponsor or any of its Affiliates (other than Parent and Merger Sub), on the one hand, and Parent or any of its Affiliates (other than a Sponsor), on the other hand, with respect to the subject matter hereof.  Except as expressly permitted in Section 1 and Section 6, no transfer of any rights or obligations hereunder shall be permitted without the consent of Parent, each Sponsor and the Company.  Any transfer in violation of the preceding sentence shall be null and void.

2

6.          Assignment.  Each Sponsor may assign all or a portion of its obligations to fund the Commitment to any of its Affiliates; provided, however, that (a) no such assignment shall relieve such Sponsor from any of its obligations hereunder and Parent shall not be required to seek to enforce its rights hereunder against any assignee prior to seeking to enforce its rights hereunder against such Sponsor and (b) such assignment does not result in any additional consent or approval of, or filing, declaration or registration with, any Governmental Authority being required to consummate the transactions contemplated by the Merger Agreement or have the effect of preventing, impairing or delaying the transactions contemplated by the Merger Agreement or the funding of the Commitment.  Notwithstanding anything to the contrary set forth herein, Parent may assign its rights under this letter agreement to any Person to which Parent assigns its interest in the Merger Agreement in accordance with the Merger Agreement.

7.          Governing Law; Jurisdiction; Service of Process.  This letter agreement, and all claims or causes of action (whether in contract, tort or otherwise) that may be based upon, arise out of, or related to this letter agreement or the negotiation, execution or performance of this letter agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in connection with this letter agreement), shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws.  Each of the parties hereby irrevocably and unconditionally (a) submits, for itself and its property, to the exclusive jurisdiction of the Delaware Court of Chancery (or, only if the Delaware Court of Chancery lacks subject matter jurisdiction, the state or federal courts in the State of Delaware), and any appellate court from any thereof, in any Action arising out of or relating to this letter agreement or the negotiation, execution or performance of this letter agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this letter agreement), or for recognition or enforcement of any judgment, and agrees that all claims in respect of any such Action shall be heard and determined in such Delaware Court of Chancery (or, only if the Delaware Court of Chancery lacks subject matter jurisdiction, the state or federal courts in the in the State of Delaware), (b) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any Action arising out of or relating to this letter agreement or the negotiation, execution or performance of this letter agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this letter agreement) in the aforementioned courts, (c) waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the maintenance of such Action in any such court and (d) agrees that a final judgment in any such Action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. Each of the parties agrees that service of process, summons, notice or document by registered mail addressed to it at the applicable address set forth in this letter agreement shall be effective service of process for any Action brought in any such court.

3

8.         Waiver of Jury Trial.  THE PARTIES HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS LETTER AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THE ACTIONS OF THE PARTIES IN THE NEGOTIATION, EXECUTION, PERFORMANCE AND ENFORCEMENT OF THIS LETTER AGREEMENT, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS SECTION 8 WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR LIMITED GUARANTY AMONG THE PARTIES IRREVOCABLY TO WAIVE TRIAL BY JURY AND THAT ANY ACTION OR PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS LETTER AGREEMENT, THE LIMITED GUARANTY OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY SHALL INSTEAD BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.
 
9.          CounterpartsThis letter agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when each party hereto shall have received counterparts hereof signed by each of the other parties hereto.  If any signature is delivered by PDF, such signature shall create a valid and binding obligation of the party executing (or on whose behalf the signature is executed) with the same force and effect as if such PDF signature were an original thereof.

10.         No Third-Party Beneficiaries.  Except as provided in Section 3 and Section 5, this letter agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder, including the right to rely upon the representations and warranties set forth herein.

11.        Confidentiality.  This letter agreement shall be treated as confidential and is being provided to Parent solely in connection with the transactions contemplated by the Merger Agreement. This letter agreement may not be used, circulated, quoted or otherwise referred to in any document (other than the Merger Agreement, the Limited Guaranty, the Proxy Statement and the Schedule 13E-3), except with the written consent of each Sponsor; provided, however, that, without the consent of each Sponsor, (i) Parent may disclose the existence of this letter agreement to the extent required by applicable Law or the applicable rules of any national securities exchange or to each party’s respective directors, employees, attorneys and other representatives, (ii) this letter agreement may be provided to the Company (so long as the Company agrees to keep, and agree to cause its Affiliates, directors, employees and attorneys to keep, this letter agreement confidential on terms that are substantially identical to the terms (and subject to the exceptions) contained in this sentence) and (iii) the Company may disclose this letter agreement (x) to its Affiliates, directors, employees and attorneys, (y) to the extent required by applicable Law or the rules of any national securities exchange and (z) in connection with any dispute or litigation relating to the Merger Agreement or the transactions contemplated by the Merger Agreement.

4

12.        Termination.  This letter agreement, and the obligation of Sponsor to fund the Commitment, will terminate automatically and immediately upon the earliest to occur of (a) the completion of the Closing (including delivery of the aggregate Per Share Merger Consideration payable to the Eligible Holders to the Paying Agent), (b) the valid termination of the Merger Agreement in accordance with its terms (provided that, for the avoidance of doubt, any purported termination of the Merger Agreement  that is not, or is later determined not to have been, a valid termination shall not give rise to a termination of this letter agreement pursuant to this clause (b)), and (c) the date of commencement by (x) the Company or any of its controlled Affiliates or (y) Parent or Merger Sub (at the written request or written direction of the Company) of an Action asserting any claim (whether in tort, contract or otherwise) under, or in respect of, the Merger Agreement, the Limited Guaranty, this letter agreement or the transactions contemplated hereby or thereby (including in respect of any oral representations made or alleged to be made in connection therewith) against any Sponsor, Parent, Merger Sub or any Sponsor Affiliate (as defined below), other than a claim (i) against any Sponsor (or its  assignees  or  successors) under the Limited Guaranty pursuant to the terms thereof and subject to the limitations set forth therein, (ii) against any Sponsor (or its assignees  or  successors) seeking specific performance of such Sponsor’s obligation to fund its Pro Rata Portion of the Commitment in accordance with the terms hereof and pursuant to, and subject to the limitations set forth in, Section 10.1 of the Merger Agreement, (iii) against Parent or Merger Sub (or  their  respective assignees or successors) under the Merger Agreement pursuant to the terms thereof and subject to the limitations set forth therein or (iv) relating to a breach of the Confidentiality Agreement (the agreements and instruments referred to in the foregoing clauses (i) through (iv), the “Excepted Agreements”).  Upon the valid termination of this letter agreement, each Sponsor and each Sponsor’s permitted assignees shall not have any further obligations or liabilities hereunder.

13.        No Recourse.  Notwithstanding anything that may be expressed or implied in this letter agreement, or any document or instrument delivered in connection herewith, by its acceptance of the benefits of this letter agreement, Parent covenants, agrees and acknowledges for itself and its Affiliates that no Person other than each Sponsor and its permitted assignees or successors has or shall have any obligation hereunder or in connection with the transactions contemplated hereby and that, notwithstanding that a Sponsor or any of its permitted assigns may be a partnership or limited liability company, except for the rights of the Company, its controlled Affiliates and/or Parent, as applicable, under the Excepted Agreements against the parties thereto, in accordance with the terms thereof and subject to the limitations set forth therein, no Person, including the Company and Parent, has any right of recovery against, and no recourse under this letter agreement or under any document or instrument delivered in connection herewith or in respect of any oral representations made or alleged to be made in connection herewith or therewith shall be had against, any former, current or future equity holders, controlling persons, directors, officers, employees, agents, Affiliates, members, managers, general or limited partners, attorneys and other representatives or assignees of any Sponsor or any former, current or future equity holder, controlling person, director, officer, employee, agent, Affiliate, member, manager, general or limited partner, other Representative or assignee of any of the foregoing (each, other than the Sponsors, Parent and Merger Sub, a “Sponsor Affiliate”), whether by the enforcement of any judgment, fine or penalty, or by any legal or equitable proceeding, or by virtue of any applicable Law, or otherwise; it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on, or otherwise be incurred by any Sponsor Affiliate, as such, for any obligation of a Sponsor under this letter agreement or the transactions contemplated hereby, in respect of any oral representations made or alleged to be made in connection herewith, or for any claim (whether in tort, contract or otherwise) based on, in respect of, or by reason of, such obligations or their creation.

5

Parent further agrees that neither it nor any of its Affiliates shall have any right of recovery against any Sponsor or any Sponsor Affiliate, whether by piercing of the corporate veil, by a claim on behalf of Parent against any Sponsor or any Sponsor Affiliate, or otherwise, except for Parent’s right to require each Sponsor to contribute capital to Parent and fund its Pro Rata Portion of the Commitment under and to the extent provided in this letter agreement subject to the terms and conditions hereof.  Parent hereby covenants and agrees that it shall not institute, and shall cause its Affiliates not to institute, any proceeding or bring any other claim (whether in tort, contract or otherwise) arising under, or in connection with, the Merger Agreement or the transactions contemplated thereby, or in respect of any oral representations made or alleged to be made in connection therewith, against any Sponsor or any Sponsor Affiliate except for claims solely against a Sponsor under this letter agreement.

14.       Representations and Warranties.  Each Sponsor hereby represents and warrants to Parent as follows:

(a)        it is a limited partnership, limited liability company, corporation or other legal entity, duly organized and validly existing under the laws of the state of its formation;

(b)        it has all limited partnership, limited liability, corporate or other applicable power and authority to execute, deliver and perform this letter agreement and consummate the transactions contemplated hereby;

(c)        the execution, delivery and performance of this letter agreement by it have been duly authorized by all necessary action and do not contravene or violate any provision of such Sponsor’s organizational documents or violate in any material respect any Law or contractual restriction binding on such Sponsor or its assets;

(d)      all consents, approvals, authorizations, permits of, filings with and notifications to, any Governmental Authority necessary for the due execution, delivery and performance of this letter agreement by such Sponsor have been obtained or made and all conditions thereof have been duly complied with, and no other action by, and no notice to or filing with, any Governmental Authority is required in connection with the execution, delivery or performance of this letter agreement, except to the extent that the occurrence of any of the foregoing items, individually or in the aggregate, would not reasonably be expected to materially delay or impair the ability of such Sponsor to perform its obligations under this letter agreement;

(e)      this letter agreement has been duly and validly executed and delivered by it and constitutes a legal, valid and binding obligation of such Sponsor enforceable against such Sponsor in accordance with its terms, subject to (i) the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other similar Laws affecting creditors’ rights generally, and (ii) general equitable principles (whether considered in a proceeding in equity or at law);

(f)        such Sponsor has the financial capacity to pay and perform all of its obligations under this letter agreement promptly as they become due, and all funds necessary for such Sponsor to fulfill its obligations under this letter agreement shall be available to such Sponsor for so long as this letter agreement shall remain in effect in accordance with the terms hereof; and

(g)        such Sponsor’s Pro Rata Portion of the Commitment is less than the maximum amount that such Sponsor is permitted to invest in any one portfolio investment pursuant to the terms of its constituent documents or otherwise.

[Signature Page Follows]

6

 
Very truly yours,
   
 
SPONSORS
   
 
NEA 18 VENTURE GROWTH EQUITY, L.P.
   
 
By: NEA PARTNERS 18 VGE, L.P.,
 
Its General Partner
   
 
By: NEA 18 VGE, LLC,
 
Its General Partner
   
 
By:
/s/ Stephanie Brecher
 
 
Name:
Stephanie Brecher  
 
Title:
Chief Legal Officer  
   
 
NEW ENTERPRISE ASSOCIATES 17, L.P.
 
By: NEA PARTNERS 17, L.P.,
 
Its General Partner
   
 
By: NEA 17 GP, LLC,
 
Its General Partner
   
 
By:
/s/ Stephanie Brecher
 
 
Name:
Stephanie Brecher  
 
Title:
Chief Legal Officer  

[Signature Page to Commitment Letter]


 
NEW ENTERPRISE ASSOCIATES 16, L.P.
 
By: NEA PARTNERS 16, L.P.,
 
Its General Partner
   
 
By: NEA 16 GP, LLC,
 
Its General Partner
   
 
By:
/s/ Stephanie Brecher
 
 
Name:
Stephanie Brecher  
 
Title:
Chief Legal Officer  
   
 
NEW ENTERPRISE ASSOCIATES 15, L.P.
 
BY: NEA PARTNERS 15, L.P., Its General Partner
 
BY: NEA 15 GP, LLC, Its General Partner
   
 
By:
/s/ Stephanie Brecher  
 
Name:
Stephanie Brecher  
 
Title:
Chief Legal Officer  

[Signature Page to Equity Commitment Letter]


Agreed to and accepted:
 
NH HOLDINGS 2025, INC.
     
By:
/s/ Stephanie Brecher
 
Name:
Stephanie S. Brecher
 
Title:
Authorized Signatory
 

[Signature Page to Equity Commitment Letter]


Exhibit A


Investor
Pro Rata Portion

New Enterprise Associates 15, L.P.
25%

New Enterprise Associates 16, L.P.
25%

New Enterprise Associates 17, L.P.
25%

NEA 18 Venture Growth Equity, L.P.
25%

Total
100.00%




Exhibit 107
Exhibit Fee Table

Calculation of Filing Fee Tables
SCHEDULE 13E-3
(Form Type)

NeueHealth, Inc.
NH Holdings 2025, Inc.
NH Holdings Acquisition 2025, Inc.
NH Holdings 2025 SPV, L.P.
NEA 18 Venture Growth Equity, L.P.
New Enterprise Associates 17, L.P.
New Enterprise Associates 16, L.P.
New Enterprise Associates 15, L.P.
 NEA 15 Opportunity Fund, L.P.
NEA BH SPV, L.P.
NEA BH SPV II, L.P.
NEA Ventures 2016 Limited Partnership
NEA Partners 15, L.P.
NEA Partners 15-OF, L.P.
NEA 15 GP, LLC
NEA Partners 16, L.P.
NEA 16 GP, LLC
NEA Partners 17, L.P.
 NEA 17 GP, LLC
NEA Partners 18 VGE, L.P.
NEA 18 VGE GP, LLC
NEA BH SPV GP, LLC
(Name of Registrant and Names of Persons Filing Statement)

Table 1: Transaction Valuation

 
Proposed Maximum Aggregate Value of Transaction
Fee Rate
Amount of Filing Fee
Fees to Be Paid
 $25,192,378.80(1)(2)
0.00015310
$3,856.95(2)
Fees Previously Paid
 $0
 
$3,856.95
Total Transaction Valuation
 $25,192,378.80
   
Total Fees Due for Filing
   
$0
Total Fees Previously Paid
   
$3,856.95
Total Fee Offsets
   
$3,856.95(3)
Net Fee Due
   
$0



Table 2: Fee Offset Claims and Sources

 
Registrant or Filer Name
Form or Filing Type
File Number
Initial Filing Date
Filing Date
Fee Offset Claimed
Fee Paid with Fee Offset Source
Fee Offset Claims
 
PREM 14A
001-40537
February 3, 2025
 
$3,856.95
 
Fee Offset Sources
NeueHealth, Inc.
PREM 14A
001-40537
 
February 3, 2025
 
$3,856.95(3)

(1)
Aggregate number of securities to which transaction applies: As of January 28, 2025, the maximum number of shares of common stock of NeueHealth, Inc., par value $0.0001 per share (“Company Common Stock”), to which this transaction applies is estimated to be 3,437,203, which consists of: (a) 3,212,166 shares of Company Common Stock entitled to receive the per share merger consideration of $7.33, without interest, (b) 37 shares of Company Common Stock underlying outstanding and unexercised options to purchase shares of Company Common Stock that have a per share exercise price that is less than the per share merger consideration of $7.33, without interest (“In-the-Money Options”), and (c) 225,000 shares of Company Common Stock underlying outstanding warrants to purchase shares of Company Common Stock represented by those certain Warrant Agreements, each dated June 21, 2024, to which the Company is party (collectively, the “Company Warrants”) that are issuable and not exercised, which are entitled to receive the per share merger consideration of $7.33, without interest, minus any applicable exercise price.

(2)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): Estimated solely for the purposes of calculating the filing fee, as of January 28, 2025, the underlying value of the transaction was calculated based on the sum of (a) the product of 3,212,166 shares of Company Common Stock and the per share merger consideration of $7.33, without interest, (b) the product of 37 shares of Company Common Stock underlying In-the-Money Options and $5.46 (which is the excess of the per share merger consideration of $7.33, without interest, over the per share exercise price of the In-the-Money Options of $1.87), and (c) the product of 225,000 shares of Company Common Stock underlying outstanding Company Warrants that are issuable and not exercised and $7.32 (which is the difference between the per share merger consideration of $7.33, without interest, and the weighted average exercise price of the Company Warrants that are issuable and not exercised). In accordance with Section 14(g) of the Exchange Act, the filing fee was determined by multiplying the sum calculated in the preceding sentence by 0.00015310.

(3)
NeueHealth, Inc. previously paid $3,856.95 upon the filing of its Schedule 14A on February 3, 2025 in connection with the transaction reported hereby.


Neuehealth (NYSE:NEUE)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Neuehealth
Neuehealth (NYSE:NEUE)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Neuehealth